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6ABBREVIATIONS
ACTH adrenocorticotropin hormone
ANOVA analysis of variance
AUC(t-ti) area under the plasma drug concentration-time curve from
 t to ti hours
CBG corticosteroid-binding globulin
Cl systemic clearance
CPMP committee for proprietary medicinal products
Cmax peak concentration
CRH corticotropin-releasing hormone
CV coefficient of variation
CYP cytochrome P450
DDD defined daily dose
ECG electrocardiogram
EDTA ethylendiaminetetraacetic acid
GRE glucocorticoid regulatory element
HIV human immunodeficiency virus
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A
HPA-axis hypothalamic-pituitary-adrenal axis
HPLC high-performance liquid chromatography
IBW ideal body weight
kel elimination rate constant
LC/MS/MS liquid chromatography-ionspray-tandem mass spectrometry
MDR multiple drug resistance
MI-complex metabolic intermediate complex
P-gp P-glycoprotein
QT QT interval in electrocardiogram
QTc heart rate-corrected QT interval
SD standard deviation
SEM standard error of mean
tmax time of peak concentration
t½ elimination half-life
Vd volume of distribution
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ABSTRACT
The aim of this thesis was to investigate the effect of CYP3A4 inhibitors on the
pharmacokinetics and pharmacodynamics of systemic glucocorticoids; the
effect of itraconazole on oral and intravenous methylprednisolone, on oral
prednisolone, and on oral and intravenous dexamethasone; and the effect of
diltiazem, mibefradil, and grapefruit juice on oral methylprednisolone. The
effect of route of administration of methylprednisolone and dexamethasone on
the possible interaction with itraconazole was also evaluated.
A total of 8 to 10 healthy subjects were enrolled in each study. Each was a
double-blind, randomised, placebo-controlled, cross-over study, except the
grapefruit juice-methylprednisolone interaction study, with its open, randomised
cross-over design. The pretreatment was followed by a single dose of
glucocorticoid, blood samples were collected and plasma drug and cortisol
concentrations determined.
The use of itraconazole enhanced the adrenal-suppressant effect of both
methylprednisolone and dexamethasone. Itraconazole increased the AUC of
oral and intravenous methylprednisolone and oral and intravenous
dexamethasone 3.9-fold (p <0.001), 2.6-fold (p <0.001), 3.7-fold (p <0.001),
and 3.3-fold (p <0.001), respectively. In contrast, itraconazole increased the
AUC of oral prednisolone by only 24% (p <0.001), and the adrenal-suppressant
effect of prednisolone was slightly enhanced. Both diltiazem and mibefradil
increased the AUC of oral methylprednisolone (2.6-fold and 3.8-fold; p <0.001)
and its adrenal-suppressant effect was greatly enhanced. Grapefruit juice
increased the AUC of oral methylprednisolone by 75% (p <0.001), but its
adrenal-suppressant effect was not significantly affected. The route of
methylprednisolone and dexamethasone administration may have only a minor
effect on the extent of itraconazole-methylprednisolone and itraconazole-
dexamethasone interactions. Despite the differences seen in pharmacokinetic
interactions, the extent of the adrenal-suppressant effect was similar after a
single oral or intravenous dose of these glucocorticoids.
In conclusion, these interactions probably result from inhibition of the CYP3A4
enzyme both during the first-pass and the elimination phases. Inhibition of the
P-glycoprotein may have contributed to the interactions of methylprednisolone
and dexamethasone. Care should be taken if methylprednisolone or
dexamethasone is used concomitantly with a potent inhibitor of CYP3A4 over a
long period. However, the itraconazole-prednisolone and grapefruit juice-
methylprednisolone interactions are probably of limited clinical significance.
INTRODUCTION
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INTRODUCTION
The cytochrome P450 (CYP) enzymes catalyse the oxidative metabolism of
many drugs (Pelkonen et al 1998, Dresser et al 2000). Among the human drug-
metabolising CYP enzymes, CYP3A4 is the most abundant enzyme both in the
liver and intestine (Shimada et al 1994, de Waziers et al 1990).
Because several drugs and also dietary factors can inhibit the catalytic activity of
CYP3A4 (Pelkonen et al 1998, Evans 2000), inhibitors of CYP3A4 can increase
exposure to drugs metabolised mainly via this pathway. Drug-drug interactions
can therefore significantly enhance both the therapeutic effects of the drug and
also the risk of adverse effects (Dresser et al 2000). For example, concomitant
use of itraconazole with commonly used drugs like terfenadine, midazolam, and
simvastatin is associated with potentially serious adverse effects (Pohjola-
Sintonen et al 1993, Olkkola et al 1994, Segaert et al 1996). However, enzyme
inhibition may also result in therapeutic failure if the drug is administered as an
inactive prodrug and its metabolic activation is inhibited (Lin et Lu 1998).
Many important drug-drug interactions have been reported after the drug in
question has received marketing approval. Some interactions have been serious
enough to cause limitations in the use of the drug or even its withdrawal from the
market. Concern for the safe use of drugs has increased, and the drug interaction
potential of a new investigational compound has to be evaluated before
marketing approval (Note for guidance on the investigation of drug interactions,
CPMP, 1997). In vitro studies are used, for example, to give information about
specific CYP enzymes involved in the metabolism of new compounds and
possible drug-drug interactions. However, an interaction observed in an in vitro
study should be confirmed in relevant, controlled in vivo studies.
Intravenous and oral glucocorticoids have been widely used for many decades in
various clinical conditions for their anti-inflammatory and immunosuppressive
properties (Hench et al 1949, Swartz and Dluhy 1978, Mies et al 1998). Systemic
glucocorticoids are eliminated mainly by metabolism (Vree et al 1999, Begg et al
1987, Tomlinson et al 1996), and inhibition of the catalytic activity of CYP3A4
by other drugs or dietary constituents can affect their elimination. CYP3A4
enzyme, however, probably has a dissimilar role in the metabolism of different
glucocorticoids.
The purpose of the present study was to investigate the potential of CYP3A4
inhibitors to affect the pharmacokinetics and adrenal-suppressant effect of
systemic methylprednisolone, prednisolone, and dexamethasone in controlled
clinical studies in healthy volunteers. Furthermore, the effect of the route of
glucocorticoid administration on the interaction potential was evaluated.
REVIEW OF THE LITERATURE
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REVIEW OF THE LITERATURE
1. Drug metabolism
1.1. Principles of drug metabolism
Most pharmacologically active compounds are lipophilic because lipophilicity
enables them to pass through biological membranes. In order to be excreted from
the body, these lipophilic compounds must be biotransformed into more water-
soluble metabolites (Meyer 1996). Metabolites generated are generally
pharmacologically less active than the parent drug or even inactive, but the
metabolites may also show enhanced pharmacological activity. Furthermore, the
metabolism of drugs can produce harmful reactive and toxic products, which may
be responsible for various forms of toxicity, e.g., hepatotoxicity (Nelson et al
1996, Mitchell et al 1974).
One major enzyme system involved in drug biotransformation is the cytochrome
P450 (CYP) monooxygenase system. Other important enzymes include esterases,
epoxide hydrolase, and conjugating enzymes such as glucuronosyltransferases
and sulfotransferases. These metabolic reactions are divided into functionalisation
(phase I) and conjugation (phase II) reactions (Meyer 1996). The phase I
oxidative biotransformations catalysed by the hepatic and extrahepatic CYP
enzymes include oxidation, reduction, and hydrolysis. Oxidative metabolism
represents a major route of elimination for many drugs (Lin and Lu 1998).
During phase II reactions, the parent drug or its phase I metabolite is conjugated
with an endogenous substrate. The phase II conjugation reactions involve
glucuronidation, sulphation, acetylation, and conjugation with glutathione. The
conjugated metabolites are usually highly water-soluble and are readily excreted
into urine and bile, which are the main routes of elimination for most drugs
(Meyer 1996).
1.2. The CYP enzymes
CYP enzymes are a family of enzymes which are found not only in human beings
but also in bacteria, fungi, plants, and animals (Nelson et al 1999). CYP enzymes
are membrane-bound, localised to the endoplasmic reticulum (Meyer 1996). They
are responsible for most of the oxidative metabolism of both xenobiotics and
endogenous substrates (Dresser et al 2000, Lin and Lu 1998).
The nomenclature of all CYP enzymes is based on their amino acid sequence
(Nelson et al 1996). The CYP enzymes within the same family are designated by
an Arabic numeral (e.g., CYP3) and share more than 40% identity in the amino
REVIEW OF THE LITERATURE
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acid sequence. The families are further divided into subfamilies, with the
enzymes within a subfamily designated by a capital letter (e.g., CYP3A) and
sharing more than 55% identity in the amino acid sequence. Finally, an Arabic
numerical after the letter denotes each individual isoenzyme (e.g., CYP3A4).
Functionally, the CYP enzymes are divided into two major classes, those with a
specific role e.g, in steroid biosynthesis, bile and arachidonic acid metabolism
(CYP4, CYP5, and higher) and those primarily involved in the metabolism of
xenobiotics such as drugs, anti-oxidants, and chemicals (CYP1, CYP2, CYP3)
(Nelson et al 1999). Many of these enzymes are involved in metabolism of a wide
range of different substrates, e.g., endogenous compounds, chemicals, and natural
plant products (Nelson et al 1996). Among the 17 CYP gene families reported in
humans by Nelson in 1999, three families: CYP1, CYP2, and CYP3, are
important for hepatic drug metabolism (Wrighton et al 1996). The most
prominent CYP isoenzymes with regard to the number of substrate drugs are
CYP3A4 and CYP2D6, with a smaller number of drugs metabolised by CYP2C9,
CYP2C19, CYP1A2, and CYP2E1 (Wrighton and Stevens 1992, Meyer 1996).
CYP enzymes are found mainly in the liver, which plays the major role in human
drug metabolism, but they are present in lower amounts in many extrahepatic
tissues (Krishna and Klotz 1994).
The expression and catalytic activity of CYP enzymes may vary greatly between
individuals, due to genetic, non-genetic endogenous (e.g. diseases), and
environmental (drugs, diet) factors (Pelkonen et al 1998). Genetic polymorphism
greatly affects the activity of some CYP enzymes, e.g., CYP2C19 and CYP2D6
(Wrighton et al 1996, Nakamura et al 1985). Furthermore, some CYP enzymes
are inducible by environmental factors such as drugs (Wrighton et al 1996,
Pelkonen et al 1998). In addition, catalytic activity of CYP enzymes can be
inhibited, or the CYP enzymes can be inactivated. Induction and inhibition of
CYP enzymes increase the intraindividual and interindividual variability of drug
metabolism. Examples of the substrates, inhibitors, and inducers of CYP3A4,
CYP2D6, CYP2C9, CYP2C19, CYP1A2, and CYP2E1 isoenzymes are presented
in Table I (page 12).
1.3. CYP3A subfamily
The CYP3A subfamily is involved in the metabolism of a large number of
endogenous and exogenous compounds, e.g., cortisol, testosterone, cyclosporin,
midazolam, nifedipine, and simvastatin (Table I). Because approximately 40-50%
of the drugs used in man are metabolised at least partly by CYP3A-mediated
REVIEW OF THE LITERATURE
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Table I. Examples of substrates, inhibitors, and inducers of the main human
hepatic drug-metabolising CYP enzymes and their relative amounts of the total
hepatic CYP content. * indicates that the enzyme exhibits genetic polymorphism.
Modified from Bertz and Granneman (1997) and Pelkonen et al (1998).
CYP enzyme Substrates Inhibitors Inducers
CYP2C19*
< 5%
omeprazole
mephenytoin
diazepam
fluoxetine
fluvoxamine
rifampicin
CYP2C8/9*
∼ 20%
warfarin
phenytoin
cerivastatin
sulphaphenazole
fluconazole
rifampicin
CYP3A4
∼ 30%
simvastatin
midazolam
triazolam
nifedipine
cyclosporin
cisapride
testosterone
ethinylestradiol
cortisol
terfenadine
ketoconazole
itraconazole
diltiazem
verapamil
grapefruit juice
erythromycin
chlarithromycin
rifampicin
phenytoin
carbamazepine
CYP1A2
∼ 15%
caffeine
theophylline
clozapine
fluvoxamine smoking
rifampicin
CYP2E1
< 10%
ethanol
halothane
chlorzoxazone
disulfiram ethanol
isoniazide
CYP2D6*
<5%
dextrometorphan
debrisoquine
codeine
metoprolol
quinidine
fluoxetine
not inducible
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oxidation, it appears to be the most important drug-metabolising CYP subfamily
(Thummel and Wilkinson 1998).
CYP3A consist of three isoenzymes, CYP3A4, CYP3A5, and CYP3A7
(Wrighton and Stevens 1992, de Wildt et al 1999). Among these, CYP3A4 is the
most abundant isoenzyme in adult liver, accounting for about 30% of total CYP
content (Shimada et al 1994). CYP3A4 is shown to be present also e.g, in small
intestine, colon, and stomach (de Waziers et al 1990). CYP3A5 is found in 25-
30% of adult livers (Wrighton and Stevens 1992). More recently, however,
CYP3A5 protein was detected in 74% of livers examined (Jounaidi et al 1996).
CYP3A5 is the major isoenzyme in the lung tissue, in which CYP3A4 is
expressed in only the minority of cases (Kivistö et al 1996a, Anttila et al 1997).
Furthermore, CYP3A5 is expressed in the small intestine in 70 to 100% of
individuals (Lown et al 1994, Kivistö et al 1996b).
CYP3A5 displays 84% similarity in its amino acid sequence to CYP3A4
(Aoyama et al 1989). Although the substrate specificity of CYP3A5 is similar to
that of CYP3A4, differences exist in these isoensymes’ catalytic properties
(Wrighton and Stevens 1992). In contrast to CYP3A4, CYP3A5 does not appear
to metabolise erythromycin, quinidine, or 17α-ethinylestradiol at significant rates
(Wrighton et al 1990). Furthermore, testosterone, cortisol, and nifedipine are
metabolised by CYP3A5 at a slower rate than by CYP3A4 (Wrighton et al 1990).
CYP3A7 is the major CYP isoenzyme in the fetal liver, accounting for up to 50%
of total CYP content (Kitada et al 1985, Wrighton and VandenBranden 1989). In
the adult liver, CYP3A7 mRNA is found in about 55 to 85%  of samples, although
at lower levels than CYP3A4 (Schuetz et al 1994, Hakkola et al 1994).
In vitro, the expression and catalytic activity of hepatic CYP3A4 can vary as
much as 6-fold and 30-fold, respectively (Shimada et al 1994, Yun et al 1993).
Despite this large interindividual variation in CYP3A4 activity, CYP3A4 does not
appear to be subject to genetic polymorphism, in contrast to CYP2C9, CYP2C19,
and CYP2D6 (Aithal et al 1999, Gaedigk 2000). Recent studies have, however,
identified a mutation in the CYP3A4 that has been linked to tumour stage and
grade at the time of diagnosis of prostatic cancer (Rebbeck et al 1998)
Furthermore, this variation may influence the risk of treatment-related leukemias
(Felix et al 1998). A recent study has found this promoter region polymorphism
not to affect the CYP3A4-mediated metabolism of erythromycin or the
pharmacokinetics of nifedipine (Ball et al 1999). Sata et al (2000) have identified
other variant alleles of CYP3A4 designated CYP3A4*2 and CYP3A4*3;
CYP3A4*2, which is present at a frequency of 2.7% in a white Finnish
population, showed in vitro altered catalytic activity compared with that of wild-
type P450 (Sata et al 2000). However, the impact of these mutations on CYP3A4
REVIEW OF THE LITERATURE
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activity and on the pharmacokinetics of CYP3A4 substrates needs further
evaluation.
Erythromycin is metabolised about 25% more rapidly by microsomes from
female than from male human liver (Hunt et al 1992). Furthermore, midazolam is
cleared 20-40% faster by women than by men (Harris et al 1995). Not all studies,
however, have found a sex-related difference in CYP3A4 activity (Schmucker et
al 1990, Shimada et al 1994). Neither menstrual-cycle phase, smoking, nor
ethanol consumption appear to influence CYP3A4 activity (Kharasch et al 1999,
Hunt et al 1992). Sotaniemi et al (1997) have suggested that liver CYP content
declines after age 40. However, two other studies have failed to find any
relationship between age and liver CYP3A activity (Hunt et al 1992, Blanco et al
2000). The CYP3A4 activity is decreased in severe liver disease (Pelkonen et al
1998), and celiac disease can decrease CYP3A4 activity in gut (Lang et al 1996).
During the last few years research interest has increasingly focused on drug
metabolism in the intestinal wall. This location makes suitable to play an
important role in first-pass metabolism and in limiting the bioavailability of orally
administered drugs (Hoppu et al 1991, Dresser et al 2000). Many CYP enzymes
including CYP3A4, CYP3A5, and CYP2D6 appear to be expressed in the
intestinal wall (de Waziers et al 1990, Kivistö et al 1996b). After the liver, the
small intestine contains the highest amount of CYP3A4 (de Waziers et al 1990).
Hepatic and intestinal CYP3A4 appear to be regulated independently (Lown et al
1994), and the content of intestinal CYP3A4 varies 11-fold and its catalytic
activity 6-fold among individuals (Lown et al 1994). This finding may contribute
to the interindividual variability in disposition of CYP3A4 substrates
administered orally. The small intestine is an important place for first-pass
metabolism of oral drugs. Interestingly, the intestinal first-pass metabolism of
some oral drugs, for example, midazolam and cyclosporin, may even exceed that
occurring in the liver (Thummel et al 1996, Wu et al 1995).
1.4. Drug interactions
Drug interaction can occur by several different mechanisms, and these can be
either harmful or beneficial. Pharmacodynamic interactions cause changes in the
effects of drugs. For example, alcohol enhances the sedative effect of
benzodiazepines (Seppälä et al 1982). Pharmacokinetic interactions can take
place at the level of drug absorption, distribution, metabolism, and excretion. For
example, antacids containing aluminium, calcium, or magnesium and iron
products reduce the absorption of tetracyclines, resulting in reduced antibacterial
effects (Neuvonen et al 1970). An example of an interaction due to changes in
REVIEW OF THE LITERATURE
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excretion is reduced excretion of penicillin by probeniside (Kampmann et al
1972).
Enzyme induction and inhibition affect drug metabolism. CYP-enzyme induction
usually results from an increased amount of enzyme protein, and a period of time
is needed before enzyme induction becomes clinically significant (Pelkonen et al
1998). Enzyme induction increases the metabolism of drugs that are metabolised
by induced enzymes, leading to decreased plasma drug concentrations (Lin and
Lu 1998). For example, rifampicin can greatly decrease the plasma concentrations
of triazolam and abolishes the effect of triazolam (Villikka et al 1997).
CYP enzyme inhibition usually occurs rapidly, even after a single dose of
inhibitor (Pelkonen et al 1998). Enzyme inhibition can be competitive or non-
competitive (Lin and Lu 1998). In case of competitive inhibition, enzyme
inhibitor competes the active site of CYP enzyme. Competitive inhibition is
probably the most common mechanism responsible for the drug-drug-
interactions. For example, itraconazole and indinavir, a potent human
immunodeficiency virus (HIV) protease inhibitor, are competitive inhibitors of
CYP3A4 (Back and Tjia 1991, Fitzsimmons and Collins 1997). Competitive
inhibitors are often substrates of the CYP isoenzyme whose activity they inhibit.
However, this is not always the case. Quinidine is a substrate for CYP3A4, but is
a potent reversible inhibitor of CYP2D6 (Guengerich et al 1986, Nielsen et al
1990).
Many drugs, including the macrolide antibiotics troleandomycin and
erythromycin, undergo metabolic activation by CYP3A4 to form inhibitory
metabolites (Pessayere et al 1982, Danan et al 1981). These metabolites can form
complexes with the enzyme called metabolic intermediate (MI) complexes,
resulting in a functionally inactive CYP3A4 enzyme. Ethinylestradiol and
grapefruit juice, for example, are classified as mechanism-based inactivators or
suicide substrates, because they cause irreversible inactivation of the enzyme
(Guengerich 1988, Lown et al 1997).
In addition to the hepatic, the intestinal CYP3A4 can be induced by such drugs as
rifampicin (Kolars et al 1992) and inhibited by known CYP3A4 inhibitors such as
ketoconazole (Tsunoda et al 1999). The orally administered drug is exposed to
CYP3A4-mediated first-pass metabolism, and inhibition of CYP-mediated
metabolism during the first-pass can result in increased bioavailability. After
intravenous administration, the drug bypasses the first-pass metabolism, and its
systemic bioavailability is complete. Thus, the effect of enzyme inhibition
depends on whether the drug is administered orally or intravenously.
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Drugs can be classified by wheather their hepatic clearance is enzyme-limited
(low; hepatic extraction ratio < 0.3) or flow-limited (high; hepatic extraction ratio
> 0.7) (Lin and Lu 1998). If the drug is metabolised mainly in the liver, decrease
in metabolic activity by enzyme inhibition results in an almost proportional
increase in the area under the plasma drug concentration-time curve (AUC) of an
orally administered drug, regadless whether the drug is a high- or low-clearance
drug (Lin and Lu 1998). However, after intravenous administration enzyme
inhibition significantly affects the AUC of a low-clearance drug, whereas the
AUC of high-clearance drug is only slightly affected (the hepatic clearance is
limited by the hepatic blood flow) (Lin and Lu 1998).
1.5. Drug interactions mediated by inhibition of CYP3A4
The drug-drug interactions mediated through CYP3A4 result either from
induction or from inhibition of this enzyme (Lin and Lu 1998, de Wildt et al
1999). Both in vitro and in vivo studies have demonstrated that CYP3A4 is
inhibited, for example, by the azole antimycotics ketoconazole and itraconazole
(Back and Tjia 1991, Varhe et al 1994, Olkkola et al 1994), the macrolide
antibiotics troleandomycin, erythromycin, roxithromycin, and clarithromycin
(Gascon et al 1991, Fleming et al 1992, Olkkola et al 1993, Backman et al 1994a,
Bailey et al 1996, Yeates et al 1996), the calcium-channel antagonists diltiazem,
verapamil, and mibefradil (Backman et al 1994b, Kantola et al 1998a, Welker et
al 1998), and by grapefruit juice (Bailey et al 1991, Hukkinen et al 1995, Lilja et
al 1998a).
Many drugs from different therapeutic areas are substrates for CYP3A4, which is
present in high amounts in both the liver and the intestine (Shimada et al 1994, de
Waziers et al 1990). Use of a CYP3A4 inhibitor can decrease drug metabolism
both during the first-pass and the elimination phases. Decreased drug elimination
may enhance a drug’s therapeutic and also its toxic effects. There are several
examples of an interaction due to inhibition of CYP3A4 being clinically
important. QT-interval prolongation or torsades de pointes ventricular arrhytmia
have been reported with concomitant use of a CYP3A4 inhibitor with terfenadine
or cisapride (Pohjola-Sintonen et al 1993, van Haarst et al 1998, Piquette 1999).
The risk of rhabdomyolysis appeared to increase with co-administration of a
CYP3A4 inhibitor and lovastatin or simvastatin (Neuvonen and Jalava 1996,
Neuvonen et al 1998, Lees and Lees 1995). Furthermore, concomitant use of
drugs such as ketoconazole, itraconazole, or verapamil increases the sedative
effects of midazolam and triazolam (Olkkola et al 1994, Backman et al 1994b,
Varhe et al 1994).
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Drug-drug interactions can also prove useful. The reduction in cyclosporin dosage
would result in extensive cost savings (Jones et al 1997, Martin et al 1999).
Concomitant use of ketoconazole with cyclosporin allows the reduction of
cyclosporin dosage by 70 to 85% in renal-, cardiac-, and liver-transplant patients.
1.6. CYP3A4 inhibitors studied
1.6.1. Itraconazole
Itraconazole is a triazole antimycotic introduced onto the market in the early
1990’s. Itraconazole inhibits the fungal CYP enzyme 14-demethylase, thereby
inhibiting the conversion of lanosterol to ergosterol, the primary sterol in fungal
membranes. The azole antifungals are primarily fungistatic (Gupta et al 1994).
Itraconazole is used in treatment and prevention of systemic fungal infections and
in oral therapy of superficial dermatomycoses such as onychomycosis (Gupta
1994, Huijgens et al 1999, Harari 1999, Venkatakrishnan et al 2000). The
recommended daily dose is 100 to 400 mg for superficial infections, but doses up
to 800 mg/day may be needed for treatment of systemic mycoses (Sanchez et al
1995). Itraconazole is usually well tolerated; incidence of adverse effects is 7%,
rising to 12.5% with therapy longer than one month. The most common adverse
effects are gastrointestinal symptoms, headache, dizziness, and rash. Furthermore,
elevation of transaminases has occurred in 0.3 to 5% of patients (Gupta et al
1994). Unlike ketoconazole, itraconazole has no significant effect on adrenal
function and plasma cortisol concentration at doses up to 400 mg daily (Gupta et
al 1994, Phillips et al 1987, Queiroz-Telles et al 1997).
Itraconazole is well absorbed when administered with a meal, but its absorption is
reduced during fasting (Van Peer et al 1989). The time of the peak concentration
(tmax) in plasma ranges from 1.5 to 4 h (Hardin et al 1988). It is highly bound to
plasma proteins (Grant and Clissold 1989, Gupta et al 1994). About 95% is bound
to plasma protein, mainly albumin, 5% to blood cells, and only 0.2 to 3% remains
free in plasma (Arredondo at al 1995, Grant and Clissold 1989, Backman et al
2000). The volume of distribution (Vd) of itraconazole is about 11 l/kg, which
indicates extensive tissue distribution (Heykants et al 1989). Due to its
lipophilicity, concentrations of itraconazole are 3 to 10 times as high in skin, and
10 to 20 times as high in liver as in plasma (Heykants et al 1989, Backman et al
2000). Itraconazole exhibits non-linear pharmacokinetics at therapeutic doses.
The mean AUC increases more than proportionally with dose, suggesting
saturable metabolism (Hardin et al 1988, Van Peer et al 1989). The elimination
half-life (t½) of itraconazole after a single dose ranges from 15 h to 25 h and at
steady state from 30 h to 50 h (Heykants et al 1989).
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Itraconazole has a significant first-pass metabolism and is eliminated by
metabolism. More than 30 metabolites have been found, but only
hydroxyitraconazole possesses clinically significant activity (Heykants et al
1989). CYP3A4 appears to have an important role in metabolism of itraconazole
(Ducharme et al 1995a). About 54% of an oral dose is excreted in faeces and 35%
in urine (Heycants et al 1989).
It had been suggested that itraconazole is a selective inhibitor of fungal CYP
enzymes and will not inhibit drug metabolism in humans (Grant and Clissold
1989). However, it is known today that itraconazole inhibits the metabolism of
many CYP3A4 substrates and causes many clinically significant drug-drug
interactions. Itraconazole has increased the AUC of midazolam and triazolam 11-
and 27-fold, respectively and markedly enhanced their hypnotic effects (Olkkola
et al 1994, Varhe et al 1994). In addition, itraconazole has increased the AUC of
buspirone about 20-fold and increased its pharmacodynamic effects (Kivistö et al
1997). Plasma concentrations of lovastatin, lovastatin acid, simvastatin, and
simvastatin acid are greatly increased by itraconazole (Neuvonen and Jalava
1996, Kivistö et al 1998, Neuvonen et al 1998). Importantly, concomitant use of
itraconazole and certain HMG-CoA reductase inhibitors may increase risk of
myalgia, and cases of rhabdomyolysis have been reported (Lees and Lees 1995,
Segaert et al 1996). Furthermore, itraconazole inhibits the metabolism of
terfenadine, resulting in increased risk for torsades de pointes ventricular
tachycardia (Pohjola-Sintonen et al 1993).
Itraconazole potently inhibits P-glycoprotein (P-gp) in vitro and probably also in
vivo (Miyama et al 1998, Kurosawa et al 1996, Backman et al 2000). P-gp and
CYP3A show substrate overlap (Wacher et al 1995), although the CYP3A4
substrate midazolam, for instance, is not a substrate of P-gp (Kim et al 1999). The
relative role of P-gp- and CYP3A-inhibition to the effect of itraconazole on the
pharmacokinetics of dual substrates of P-gp and CYP3A is unclear
(Venkatakrishnan et al 2000).
A summary of selected characteristics of itraconazole, diltiazem, mibefradil, and
grapefruit juice is shown in Table II (page 23).
1.6.2. Diltiazem
Diltiazem is a benzothiazepine calcium-channel blocker used in treatment of
angina pectoris, hypertension, and supraventricular arrhythmias (Dollery 1999a,
Buckley et al 1990). Diltiazem inhibits the influx of calcium into vascular smooth
muscle and myocardial cells through ”slow” calcium channels and thereby
reduces the tone of coronary and peripheral arterioles (Jones and Hall 2000). The
recommended oral daily dose of diltiazem ranges from 120 to 360 mg divided
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into one to three doses (Buckley et al 1990). Diltiazem is usually well tolerated;
the incidence of adverse effects is less than 2% (McGraw et al 1982). The most
common adverse effects are related to the vasodilator properties of diltiazem, like
flushing, headache, ankle oedema, and hypotension.
Diltiazem is almost completely absorbed after oral administration; it undergoes a
significant first-pass metabolism, resulting in a bioavailability of only about 40%
(Kelly and O’Malley 1992). The peak plasma concentration (Cmax) is reached
within 1.5 h with fast-release formulation (Buckley et al 1990).
Diltiazem is about 80 to 90% bound to plasma proteins, mainly albumin (Buckley
et al 1990). The Vd of diltiazem is about 5.0 l/kg (Hermann et al 1983). It is
largely eliminated through CYP3A4-mediated metabolism (Pichard et al 1990,
Sutton et al 1997). About 70% of the dose is excreted into the urine and 17% into
the faeces (Höglund and Nilsson 1988). Metabolites of diltiazem possess
pharmacologic activity, but their role in therapeutic effects is unclear (Jones and
Hall 2000). The t½ of orally administered diltiazem averages about 4.5 h (range 2-
11 h) (Buckley et al 1990). Multiple oral dosing with diltiazem results in
prolongation of its elimination, which may be due to inhibition of diltiazem
metabolism by diltiazem itself or by accumulated metabolites (Tsao et al 1990).
The ability of diltiazem to inhibit microsomal drug oxidation was first reported by
Renton in 1985. More recently, in a study in human liver microsomes, both
diltiazem and its metabolites inhibit CYP3A4 (Sutton et al 1997). However, the
N-desmethyl and N,N-didesmethyl metabolites were much more potent inhibitors
of CYP3A4 than the parent drug itself (Sutton et al 1997, Jones and Hall 2000).
Thus, the metabolites of diltiazem probably contribute to enzyme inhibition and
drug-drug interactions in vivo (Sutton et al 1997, Jones and Hall 2000).
In humans, the plasma concentrations of several CYP3A4 substrates such as
cyclosporin, midazolam, triazolam, and simvastatin are increased by diltiazem
(Pochet and Pirson 1986, Brockmöller at al 1990, Backman et al 1994b, Varhe et
al 1996, Mousa et al 2000). Furthermore, diltiazem increases the concentrations
of carbamazepine, resulting in its enhanced neurotoxicity (Brodie and MacPhee
1986, Eimer and Carter 1987). In addition, diltiazem has been shown to increase
the metabolic ratio of debrisoquine, indicating its potential to inhibit the CYP2D6
enzyme (Sakai et al 1991). Because diltiazem does not significantly affect hepatic
blood flow (Bauer et al 1986), the changes in drug metabolism are most probably
due to the inhibition of CYP enzymes by diltiazem and/or its metabolites.
Diltiazem is also an inhibitor of P-gp (Cornwell et al 1987), and may thereby
affect the pharmacokinetics of substrates of P-gp. In fact, diltiazem can prolong
the t½ and decrease the Cl of digoxin, which is actively secreted by P-gp in renal
tubular cells (Rameis et al 1984, de Lannoy and Silverman 1992).
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1.6.3. Mibefradil
Mibefradil belongs to a new class of calcium blockers; unlike traditional calcium
blockers, it selectively blocks T-type (transient, low-voltage-activated) calcium
channels (Welker et al 1998). Mibefradil can thus serve as an oral treatment for
hypertension and stable angina pectoris. It dilates the peripheral and coronary
vessels, which results in a reduction in arterial pressure and peripheral vascular
resistance, and an increase in coronary artery blood flow (Welker et al 1998).
Mibefradil reduces heart rate dose-dependently and does not cause reflex
tachycardia, as is commonly seen with dihydropyridine calcium blockers (Welker
et al 1998). The recommended dosage is 50 to 100 mg once daily.
About 99.5% of mibefradil is bound to plasma proteins, mainly to α1-acid
glycoprotein (Welker et al 1998). The Vd of mibefradil in the steady state ranges
from 130 l to 200 l (Dollery 1999b, du Souich et al 2000). Mibefradil exhibits
dose- and time-dependent pharmacokinetics that can be explained by partial
saturation of the metabolism or by inhibition of mibefradil metabolism by
mibefradil itself or by accumulated metabolites (du Souich et al 2000). Its t½
averages 15 h, with a range of about 10 to 38 h (Dollery 1999b, Welker et al
1998, du Souich et al 2000).
Mibefradil is eliminated largely by metabolism, and excreted mainly in the faeces
(75%), to a lesser extent in the urine (25%); less than 3% is excreted unchanged
in the urine. The metabolism of mibefradil is mediated by two main pathways,
CYP3A4-mediated oxidation and hydrolysis of the ester side-chain. Such
hydrolysis produces Ro 40-5966, which is, however, the major plasma metabolite,
possessing about 10% of the pharmacodynamic activity of the parent drug
(Welker et al 1998). A total of some 30 metabolites of mibefradil have been
detected (Wiltshire et al 1997).
In vitro studies on human liver microsomes have shown mibefradil to be a potent
inhibitor of CYP3A4 and CYP2D6 (Welker et al 1998, Wang et al 1999, Bohets
et al 2000). In vivo, mibefradil has increased the total AUC of CYP3A4 substrates
cyclosporin and triazolam 2.7-fold and 9-fold, respectively, and enhanced the
sedative effects of triazolam (Welker et al 1998, Backman et al 1999). In
addition, mibefradil raises the plasma concentration of terfenadine and the mean
QTc interval, resulting in an increased risk for cardiac arrhythmias (Welker et al
1998). Mibefradil also considerably increases plasma concentrations of
metoprolol, a substrate of CYP2D6 (Welker et al 1998). Besides inhibiting
CYP3A4, mibefradil also inhibits P-gp in vitro (Wandel et al 2000). However, in
humans mibefradil raises plasma concentrations of digoxin only at
supratherapeutic levels (Siepmann et al 1995, Welker et al 1998).
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Mibefradil was withdrawn from the market in 1998, within its first year after
launch, because of severe interactions with other drugs (Ellison 1998, Mullins et
al 1998, Schmassmann-Suhijar et al 1998, Krähenbühl et al 1998, Anonymous
1998).
1.6.4. Grapefruit juice
A finding in 1989 in an ethanol-felodipine interaction study suggested that
grapefruit juice may increase the bioavailability of felodipine (Bailey et al 1989).
This observation was confirmed in a subsequent study, in which the mean AUC
of felodipine was increased 284% by grapefruit juice (Bailey et al 1991).
Grapefruit juice has been shown also to raise plasma concentrations of other
dihydropyridine calcium-channel blockers such as nifedipine, nisoldipine, and
nitrendipine (Bailey et al 1991, Bailey et al 1993a, Soons et al 1991). Grapefruit
juice has increased the AUC of orally administered midazolam by 52% and
enhanced its effects (Kupferschmidt et al 1995). However, Vanakoski et al (1996)
found no interaction between grapefruit juice and oral midazolam. In addition,
grapefruit juice has increased the plasma concentrations of such drugs as
cyclosporin, terfenadine, and cisapride (Ducharme et al 1995b, Benton et al 1996,
Kivistö et al 1999). Grapefruit juice appears to affect particularly those drugs with
an extensive CYP3A4-mediated first-pass metabolism. It has greatly increased the
AUC of of simvastatin (16-fold) and simvastatin acid (7-fold), the AUC of
lovastatin (15-fold) and lovastatin acid (5-fold), and the AUC of buspirone (9-
fold) (Lilja et al 1998a, Kantola et al 1998b, Lilja et al 1998b).
A study by Lee et al (1996) suggests that grapefruit juice inhibits 11β-
hydroxysteroid dehydrogenase that oxidises cortisol to cortisone. However,
grapefruit juice does not interact with prednisone and it had no effect on the
metabolism of prednisone to prednisolone, a reaction catalysed by 11β-
hydroxysteroid dehydrogenase (Hollander et al 1995).
Graprefruit juice reduces intestinal CYP3A4 without affecting hepatic CYP3A4
activity. Therefore, the most probable mechanism for grapefruit juice interactions
is inhibition of first-pass metabolism by reduced CYP3A4-mediated metabolism
in the intestine (Lown et al 1997, Evans 2000). For example, although grapefruit
juice raises plasma concentrations of oral cyclosporin, felodipine, and midazolam,
it has no effect on their clearance after intravenous administration (Ducharme et
al 1995b, Lundahl et al 1997, Kupferschmidt et al 1995).
Because grapefruit juice does not reduce the amount of CYP3A4 mRNA, it
appears to damage the CYP3A4 enzyme, resulting in accelerated degradation of
the enzyme (mechanism-based inhibition) (Lown et al 1997, Bailey et al 1998a,
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Evans 2000). This ihibition is consistent with the finding that grapefruit juice
affects felodipine pharmacokinetics even when the juice is ingested 24 h before
the drug (Lundahl et al 1995). Thus, the return of CYP3A4 activity would need de
novo enzyme synthesis (Bailey et al 1998a).
Grapefruit juice-drug interactions can be greater after repeated consumption than
after a single glass of grapefruit juice (Gross et al 1999, Kivistö et al 1999). The
AUC values of oral cisapride have been increased by about 40% and 145% after a
single glass of regular strength and after repeated doses of double-strength
grapefruit juice, respectively (Gross et al 1999, Kivistö et al 1999). In addition,
repeated consumption of double-strength grapefruit juice has increased the t½ of
oral cisapride, buspirone, and atorvastatin (Kivistö et al 1999, Lilja et al 1998b,
Lilja et al 1999). Increase in t½ indicates an effect on hepatic CYP3A4.
Accordingly, high amounts of grapefruit juice have been reported to affect both
presystemic and systemic metabolism of oral midazolam, a well-known marker of
CYP3A4 (Veronese et al 1999).
Because of the overlapping substrate specificity of CYP3A4 and P-gp (Wacher et
al 1995), it is possible that grapefruit juice affects the intestinal P-gp. Lown et al
(1997) found grapefruit juice to reduce the amount of intestinal CYP3A4 without
affecting intestinal P-gp expression. Recently grapefruit juice has been
demonstrated in vitro to inhibit vinblastine cellular efflux by P-gp (Takanaga et al
1998). Eagling et al (1999) have reported grapefruit juice components to inhibit
CYP3A4-mediated metabolism of saquinavir, and to modulate to a limited extent
P-gp-mediated transport in vitro. Eagling et al (1999) suggest that the in vivo
effects of grapefruit juice on saquinavir pharmacokinetics most likely result from
inhibition of CYP3A4 and only to a minor extent from modulation of P-gp.
It was originally thought that the flavonoid naringin, which is related to the
typical bitter taste of grapefruit juice, and is its most abundant flavonoid, is
responsible for the interaction of grapefruit juice with drugs (Bailey et al 1998a,
Evans 2000). Both naringin and its aglucone naringenin inhibit the metabolism of
felodipine and nifedipine in vitro (Bailey et al 1998b, Miniscalco et al 1992).
Also, furanocumarins can cause a mechanism-based inhibition of CYP enzymes
and a furanocumarin called 6’,7’-dihydroxybergamottin is present in grapefruit
juice (Evans 2000). However, in vivo studies show that neither naringin nor 6’,7’-
dihydroxybergamottin is the component responsible for grapefruit juice-drug
interactions in humans (Bailey et al 1993b and 1998b).
A summary of selected characteristics of itraconazole, diltiazem, mibefradil, and
grapefruit juice is shown in Table II.
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1.7. CYP3A4 and P-glycoprotein
The P-gp in humans is a MDR-1 (multiple drug resistance) gene product, which
acts as a transmembrane efflux pump. It has an important role in the development
of multidrug resistance by tumour cells exposed to cancer chemotherapeutic
agents (Sikic et al 1997). P-gp is found in a number of human organs, including
gut, liver, adrenal gland, and kidney (Thiebaut et al 1987).
P-gp has an important role in elimination of drugs into bile and urine, and in
limiting the drug penetration into brain through the blood-brain barrier (Jalava et
al 1997, Schinkel et al 1994 and 1995). P-gp and CYP3A4 are colocalised in
intestine, where they act together to limit the drug absorption into portal
circulation and to decrease plasma drug concentrations. Both P-gp and CYP3A4
are expressed and upregulated co-ordinately in human cancer cells (Schuetz et al
1996). In addition, known CYP3A4 inducers like rifampicin also induce P-gp
(Schuetz et al 1996) and many inhibitors of CYP3A4 e.g. itraconazole are also
inhibitors of P-gp (Kurosawa et al 1996, Wacher et al 1995).
Many drugs metabolised by CYP3A4 are also substrates for P-gp (Wacher et al
1995). Accordingly, the coadministration of two CYP3A4 substrates can result in
interactions that reflect inhibition of the CYP3A4-mediated metabolism, reduced
efflux by P-glycoprotein or a combination of both effects (Kivistö et al 1995).
2. Glucocorticoids
2.1. General
The adrenal glands are endocrine organs essential for life. This was established in
1849 by Addison, who described a fatal outcome in a patient with adrenal
destruction. The adrenal gland consists of cortex and medulla. The adrenal cortex
secretes corticosteroids, glucocorticoids that regulate carbohydrate and protein
metabolism, the mineralocorticoid aldosterone that regulates fluid and electrolyte
balance, and also precursors of the sex steroids. The main glucocorticoid in
humans is cortisol. (Schimmer and Parker 1996)
Chemical modifications of the cortisol molecule have generated synthetic
glucocorticoid derivates. Because effects of natural and synthetic glucocorticoids
are mediated by the same receptor, the glucocorticoids do not differ in their
effects in humans. However, changes in chemical structure may cause changes in
potencies relative to glucocorticoid and mineralocorticoid activity, alterations in
absorption, protein binding, and metabolism (Schimmer and Parker 1996). All
glucocorticoids, cortisol and its synthetic analogues, are referred as to C21
steroids (Figure 1). Some areas of the steroid molecule are critical (Figure 2), and
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alteration in any of these areas will result in loss of glucocorticoid activity
(Swartz and Dluhy 1978).
Figure 1. Structure of cortisone, hydrocortisone (cortisol), and selected synthetic
glucocorticoids.
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Figure 2. Groups/areas essential for anti-inflammatory activity of glucocorticoids
(Adapted from Swartz and Dluhy 1978)
Synthetic corticosteroids are grouped according to their relative potencies in Na+
retention and anti-inflammatory effects in relation to cortisol (Table III). Based
on these potencies, synthetic corticosteroids are divided into glucocorticoids and
mineralocorticoids, although some steroids traditionally classified as
glucocorticoids, such as prednisolone, also possess some mineralocorticoid
activity. Synthetic glucocorticoids with long plasma half-lives also possess long
biological half-lives, reflecting the duration of the activity at tissue level (Table
III) (Swartz and Dluhy 1978, Schimmer and Parker 1996).
Table III. Relative potencies of some natural and synthetic glucocorticoids
(Modified from Swartz and Dluhy 1978, Schimmer and Parker 1996)
Compound Equivalent
potency (mg)
Anti-
inflammatory
potency
Na+-
retaining
potency
Biological
half-life (h)
Cortisol 20 1 1 8-12
Cortisone 25 0.8 0.8 8-12
Prednisone 5 4 0.8 18-36
Prednisolone 5 4 0.8 18-36
Methylprednisolone 4 5 0.5 18-36
Dexamethasone 0.75 25 0 36-54
REVIEW OF THE LITERATURE
27
2.2. Regulation of cortisol secretion
The main glucocorticoid of human beings is cortisol (hydrocortisone). The
secretion of cortisol follows a circadian diurnal variation with peak
concentrations in the morning and the lowest concentrations occurring
approximately at midnight (Jusko et al 1975, Meibohm et al 1999). Esteban et al
(1991) suggest that cortisol secretion rather than metabolism is mainly
responsible for the changes in plasma cortisol.
Hypothalamus, pituitary, and adrenal cortex are collectively called the
hypothalamic-pituitary-adrenal (HPA) axis. This system is responsible for the
diurnal rhythm in basal cortisol secretion and the increase in cortisol secretion in
stress, e.g., in infection or surgery (Naito et al 1992). The adrenocorticotropin
hormone (ACTH), which is secreted by the anterior pituitary gland, stimulates the
secretion of cortisol. The secretion of ACTH is regulated by a hypothalamic
hormone, corticotropin-releasing hormone (CRH). Cortisol has negative feedback
effects on the hypothalamus and anterior pituitary gland to reduce formation of
CRH and ACTH and thereby can control its own secretion.
2.3. Pharmacodynamics
Intracellular action of glucocorticoids. Glucocorticoids enter the target cell and
bind the glucocorticoid receptor in cytoplasm. This binding activates the receptor
that moves into the nucleus and binds to specific glucocorticoid regulatory
elements (GREs). Glucocorticoids mainly increase the expression of the target
genes. They can, however, also suppress gene transcription. Glucocorticoids have
widespread actions affecting many cells and tissues (Schimmer and Parker 1996,
Berne and Levy 1998).
Carbohydrate, protein, and lipid metabolism. In the liver, glucocorticoids
enhance the formation of glucose from amino acids and glycerol, and the
deposition of glucose as glycogen. In peripheral tissues, glucocorticoids increase
protein breakdown in muscle, bone, connective tissue, and skin. Furthermore,
glucocorticoids antagonise the effect of insulin on glucose metabolism and inhibit
insulin-stimulated glucose uptake in cells. The net effect of glucocorticoids is an
increase in blood glucose concentrations. Glucocorticoids facilitate the effect of
lipolytic substances, such as growth hormone, resulting in an increase in free fatty
acids. An excess of glucocorticoids results in the typical distribution of fat in the
back and neck, face, and abdomen, with loss of fat in the extremities.
Effects on muscle, bone, and connective tissue. Glucocorticoids reduce muscle
mass and strength and inhibit bone formation by several mechanisms. They
reduce synthesis of the type I collagen essential for bone matrix. Glucocorticoids
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reduce the availability of calcium for bone mineralisation. In addition,
glucocorticoids increase bone reabsorption. Finally, the net effect is a decrease in
bone density (osteoporosis). Glucocorticoids inhibit the synthesis of collagen,
resulting in thinning of the skin and capillary walls.
Effects on the vascular system. Glucocorticoids enhance vascular reactivity to
other vasoactive substances, e.g., angiotensin II. Glucocorticoids, even those
lacking mineralocorticoid activity, may cause hypertension, the mechanism of
which is still unclear.
Effects on the central nervous system. Glucocorticoids modulate behaviour and
mood. Lack of cortisol in Addison’s disease may cause apathy and depression. An
excess of glucocorticoids may cause insomnia, decrease memory skills, lower the
threshold to seizure activity, or even cause psychoses.
Effects on inflammatory and immune responses. Glucocorticoids reduce the
number of lymphocytes and reduce the mass of lymphoid tissue. In addition,
glucocorticoids inhibit such processes as the synthesis and release of arachinodic
acid, a precursor for many mediators of immune responses. The hormone reduces
the number and function of thymus-derived lymphocytes (T-cells), thereby
inhibiting cell-mediated immunity. The production of e.g., interleukin-1, -2, -6,
and tumour necrosis factor α is reduced. The suppression of T-cell activation also
suppresses the activation of B-lymphocytes. The net effects of these complex
actions are diminished inflammatory and immune responses.
2.4. Therapeutic use
The finding of Hench et al in 1949 that cortisone has beneficial effects in
treatment of rheumatoid arthritis generated great interest in cortisol and its
synthetic analogues. In addition to being replacement therapy for adrenal
insufficiency, glucocorticoids are widely used because of their anti-inflammatory
and immunosuppressive properties in treatment of nonendocrine diseases.
Systemic glucocorticoids are included in the standard immunosuppressive drug
regimen for organ-transplant patients (Mies et al 1998, Sarna et al 1997, Perico
and Remuzzi 1997). They are used in treatment of diseases of connective tissue,
e.g., rheumatoid arthritis, polymyositis, and systemic lupus erythematosus
(LaRochelle et al 1993, Laan et al 1999) and in treatment of acute exacerbation of
asthma (Rowe et al 2000). Many antineoplastic combinations used to treat acute
leukaemia, lymphomas, and myeloma include glucocorticoids (Gaynon and
Carrel 1999, Cain et al 1998, Oken 1997). Furthermore, renal diseases, e.g.,
nephrotic syndrome secondary to minimal change disease usually respond well to
the glucocorticoids (Friedman and Chesney 1982). In addition, glucocorticoids
are used for the management of nausea and vomiting induced by cancer
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chemotherapy and for management of brain tumours (Ater et al 1997, Perez
1998).
Usually the appropriate dose has to be determined case by case. The dosage of
glucocorticoid varies, depending on nature and severity of the disease. Prolonged
therapy with doses that exceed the normal physiological level of glucocorticoid
require careful consideration. If possible, the total daily dose should be given as a
single morning dose, and an alternate day therapy has been recommended to
minimise the catabolic actions and HPA-axis suppression of glucocorticoids
(Melby 1974, Swartz and Dluhy 1978).
Interestingly, the use of systemic glucocorticoids in Finland is steadily increasing
(Figure 3); for example by about 60% from the year 1988 to 1998 measured as
defined daily doses per 1000 inhabitants per day (DDD/1000 inh/day). In 1998,
the use of systemic glucocorticoids was 12.42 DDD/1000 inh/day, which means
62 100 DDD/5 million inhabitants every day.
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Figure 3. Use of systemic glucocorticoids in Finland, 1988-1998, in defined daily
doses per 1000 inhabitants per day (DDD/1000 inh/day) (Finnish Statistics on
Medicines 1988-1998; National Agency for Medicines and Social Insurance
Institution)
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2.5. Adverse effects of glucocorticoid treatment
Glucocorticoid adverse effects can be described as an extension of their
pharmacodynamic and physiological effects. Synthetic glucocorticoids can
suppress endogenous cortisol secretion and abolish the daily circadian rhythm of
cortisol (Salassa et al 1953, Melby 1974, Slayter et al 1996). The failure of the
adrenal gland to response to stress (infection, surgery) is one major and
unpredictable complication of glucocorticoid therapy (Fraser et al 1952, Salassa
et al 1953, Melby 1974, Henzen et al 2000). Treatment with high doses of
glucocorticoids even for less than a week and daily doses as low as 5 mg
prednisone equivalent or less can, in some sensitive individuals, impair the
adrenal response (Streck and Lockwood 1979, Schlaghecke et al 1992, Henzen et
al 2000). Neither the dose of glucocorticoid nor the duration of the treatment
appears to predict the adrenal insufficiency (Livanou et al 1967, Schlaghecke et al
1992, Henzen et al 2000).
Glucocorticoids increase the susceptibility to bacterial, viral, and fungal
infections (Twycross 1994). Severe, even fatal varicella cases have been
associated with corticosteroid use (Kasper and Howe 1990, Dowell and Bresee
1993). Glucocorticoids can cause myopathy, which may be severe enough to
disturb daily activities and even impair respiratory function (Batchelor et al
1997). Osteoporosis and vertebral compression fractures are serious
complications of glucocorticoid therapy (Adachi et al 1993). It has been estimated
that the incidence of fractures in patients receiving chronic glucocorticoid therapy
is about 30% to 50% (Adachi et al 1993). In addition, glucocorticoids can cause
hyperglycaemia and increase insulin requirements of diabetes patients (David et
al 1980, Twycross 1994). Furthermore, glucocorticoids can cause electrolyte
abnormalities, hypertension, psychiatric disorders, cataract, a typical moon-face,
striae, and truncal obesity (Melby 1974, Swartz and Dluhy 1978, Twycross 1994,
Jenkins 1999). In children treatment with glucocorticoids can result in growth
retardation (Sarna et al 1997).
2.6. Methylprednisolone
Pharmacokinetics. Methylprednisolone is rapidly absorbed following oral
administration with its Cmax reached within 1 to 3 h (Antal et al 1983, Al-Habet
and Rogers 1989). The mean absolute bioavailability of methylprednisolone is
high, ranging from 80% to 90% (Antal et al 1983, Al-Habet and Rogers 1989,
Patel et al 1993). However, Patel et al (1993) reported large interindividual
variability in absolute bioavailability, ranging from 50% to complete
bioavailability.
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Methylprednisolone is about 80% bound to plasma protein with only a little
bound to the corticosteroid-binding protein, transcortin (Szefler et al 1986, Kong
et al 1989). The mean Vd of methylprednisolone averages 1.2 to 1.5 l/kg (Al-
Habet and Rogers 1989, Kong et al 1989, Szefler et al 1986). Ferry et al (1994)
suggest that methylprednisolone exhibits dose- and time-dependent
pharmacokinetics. Others have, however, shown the pharmacokinetics to be
linear in the dose ranges 0 to 40 mg (Kong et al 1989), 20 to 80 mg (Al-Habet and
Rogers 1989), and 540 to 1026 mg (Assael et al 1982). The mean t½ of
methylprednisolone averages 1.9 to 3.3 h (Szefler et al 1986, Ferry et al 1994, Al-
Habet and Rogers 1989). The systemic plasma clearance (Cl) of
methylprednisolone averages 350 to 450 ml/h/kg (Al-Habet and Rogers 1989,
Patel et al 1993).
Due to its lipophilicity and low water-solubility, methylprednisolone itself can not
be administered intravenously. Methylprednisolone sodium succinate is a prodrug
and is hydrolysed in the body rapidly and almost completely with a half-life of
about 4 minutes to active methylprednisolone alcohol (Al-Habet and Rogers
1989).
Methylprednisolone undergoes reduction of the ketone group at the C20 position,
yielding the inactive metabolites 20α- and 20β-hydroxymethylprednisolone, and
further oxidation of the C20,C21 side chain (Stjernholm and Katz 1975, Vree et al
1999). The 6α-methyl group has been suggested to prevent the hydroxylation at
C6 position. However, Vree et al (1999) found 6β-hydroxy-6α-
methylprednisolone and a compound that might be 6α-hydroxy-6β-
methylprednisolone in the urine of patients receiving methylprednisolone.
Oxidation at C11 of methylprednisolone produces a minor metabolite,
methylprednisone; this reaction is reversible. In addition, Rodchenkov et al
(1987) found 6,7-dehydro metabolites in urine, indicating that formation of a 6,7-
double band may be possible. The suggested metabolic pathways of
methylprednisolone are presented in Figure 4. The specific CYP enzymes
involved in the various metabolic pathways of methylprednisolone have not been
determined.
After radio-labelled doses of methylprednisolone, a total of 75% of the label was
detected in urine and 20% in bile (Slaunwhite and Sandberg 1961). Furthermore,
during the first 24 h after administration of methylprednisolone sodium succinate,
about 30% of the dose was excreted in the urine: 10% as unmetabolised ester,
12% as methylprednisolone, 8% as 20α- and 1.0% as 20β-
hydroxymethylprednisolone, and less than 1.0% as methylprednisone (Lawson et
al 1992). In urine, glucuronides, sulphates and unconjugated metabolites were
present (Slaunwhite and Sandberg 1961).
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Figure 4. Metabolic pathways of methylprednisolone reported in the literature
(Adapted from Vree et al 1999).
Women appear to eliminate methylprednisolone more rapidly than do men;
however, the clinical importance of this observation is unclear (Lew et al 1993).
The Cl of methylprednisolone is slower in elderly (range 69-82 years) than in
younger (range 24-37 years) men (Tornetore et al 1994). This pharmacokinetic
alteration may increase the risk for adverse effects among elderly patients
(Tornetore et al 1994). Furthermore, the Cl of methylprednisolone was lower in
the obese than in non-obese subjects (Dunn et al 1991). The metabolism of
methylprednisolone may be impaired in severe liver disease; however, patients
with renal impairment appears to need no dose adjustment of methylprednisolone
(Dollery 1999c).
Pharmacokinetic drug interactions. Enzyme inducers phenobarbital, phenytoin,
and carbamazepine induce metabolism of methylprednisolone. Phenobarbital
increased the Cl of methylprednisolone by 208%, phenytoin by 478%, and
carbamazepine by 342%, suggesting clinically significant interactions
(Stjernholm and Katz 1975, Bartoszek et al 1987).
The effect of some CYP3A4 inhibitors on intravenous methylprednisolone has
been evaluated. Troleandomycin decreased the Cl of intravenous
methylprednisolone by 64% and increased its mean t½ from 2.5 to 4.6 h (Szefler
et al 1980). Erythromycin 250 mg 4 times daily for one week decreased the Cl of
methylprednisolone by 46% and increased its t½ by 51%, from 2.4 to 3.5 h
(LaForce et al 1983). In addition, ketoconazole increased the methylprednisolone
AUC by 135% and reduced its Cl by 66% after intravenous administration (Glynn
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et al 1986). Kandrotas et al (1987) recommend a 50% lower dose of
methylprednisolone during concomitant use of ketoconazole and
methylprednisolone.
Cimetidine did not affect methylprednisolone disposition (Green et al 1984).
Furthermore, cyclosporin appears not to affect methylprednisolone disposition
following intravenous administration of methylprednisolone (Tornatore et al
1993). Oral contraceptives decreased the Cl of intravenous methylprednisolone,
increased total AUC by 49%, and t½ from 1.7 to 2.2 h (Slayter et al 1996).
A summary of pharmacokinetic variables of methylprednisolone, prednisolone,
and dexamethasone is shown in Table IV (page 37).
2.7. Prednisolone
Pharmacokinetics. Prednisolone is rapidly absorbed after oral administration and
reaches the Cmax within approximately 1 to 2 h (Leclercq and Copinschi 1974,
Pickup 1979). The mean absolute bioavailability of prednisolone ranged from
80% to about 100% (Petereit and Meikle 1977, Al-Habet and Rogers 1980). The
protein binding of prednisolone varies from 65% to 90% (Pickup 1979).
Prednisolone is reversibly bound to albumin and to transcortin. The degree of
protein binding of prednisolone is concentration-dependent, since binding to
transcortin is saturable (Pickup 1979).
The Vd of prednisolone increases with dose from about 0.35 l/kg to 0.7 l/kg (Begg
et al 1987). In addition, the Cl of prednisolone is dose-dependent. After a 5 mg
and 40 mg dose of prednisolone the Cl has been about 7 l/h and 12 l/h,
respectively (Rose et al 1981a). These dose-dependent changes may result from a
concentration-dependent change in protein binding. Because both Vd and the Cl
increase, there may be none (Tanner et al 1979, Bergrem et al 1983) or only a
minor dose-dependent change in the t½ of prednisolone (Rose et al 1981a). The
mean t½ of prednisolone has ranged from 2.6 h to 4.5 h (Al-Habet and Rogers
1980, Rose et al 1981a, Bergrem et al 1983).
The oxidation of prednisolone at C11 position produces prednisone, a synthetic
glucocorticoid in an inactive form. This metabolic reaction is interconversible and
favours the formation of prednisolone. The concentrations of prednisolone are 4
to 10 times as high as those of prednisone after administration of either
prednisone or prednisolone (Rose et al 1981a). Prednisolone can be hydroxylated
at the 6β position like cortisol, and the urinary 6β-hydroxyprednisolone makes up
8% to 10% of the administered prednisolone dose and some 2% to 5% is excreted
as prednisone in the urine (Rose et al 1981a, Frey et al 1987, Zürcher et al 1989).
About 7% to 24% of the prednisolone dose is excreted in the urine as the parent
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drug (Rose et al 1981a, Frey et al 1987, Zürcher et al 1989). Furthermore, both
prednisone and prednisolone can undergo reduction of the ketone group at C20
(Gray et al 1956). After radiolabelled doses of prednisolone, more than 90% of
the label is detected in urine and less than 5% in bile (Slaunwhite and Sandberg
1961).
The specific CYP enzymes involved in the metabolic pathways of prednisolone
have not been determined. Based on the fact that 6β-hydroxylation of cortisol is
catalysed by CYP3A4 and CYP3A5 (Ged et al 1989, Wrighton et al 1990), these
enzymes have also been assumed to be responsible for the 6β-hydroxylation of
prednisolone, although this is a relatively minor metabolic pathway of
prednisolone.
The Cl of prednisolone appears to be slightly, about 20%, higher in females than
in males (Meffin et al 1984), the clinical significance of which remains unclear.
The Cl of prednisolone is 35% higher in obese subjects than in non-obese
subjects, and dosage should reflect total body weight (Milsap et al 1984). Its Cl
may be slightly decreased in chronic active hepatitis (Powell and Axelsen 1972);
however, in a study by Kawai et al (1985), liver disease does not affect its
pharmacokinetics. Smoking does not affect the pharmacokinetics of prednisolone
(Rose et al 1981b). In addition, results concerning the autoinduction of
prednisolone metabolism during long-term therapy are contradictory (Begg et al
1987).
Pharmacokinetic drug interactions. Rifampicin, phenobarbital, carbamazepine,
and phenytoin induce the metabolism and increase the Cl of prednisolone
(McAllistar et al 1983, Brooks et al 1976, Bartoszek et al 1987, Petereit and
Meikle 1977). Concomitant use of rifampicin or phenobarbital with prednisolone
can worsen the symptoms of the disease being treated, e.g., nephrotic syndrome
or rheumatoid arthritis (Hendrickse et al 1979, Brooks et al 1976).
Lanzoprazole and omeprazole, following prednisone administration, do not affect
the pharmacokinetics of prednisolone (Cavanaugh and Karol 1996). The
pharmacokinetics of prednisolone are altered only slightly after cimetidine and
ranitidine, and this interaction appears not to be clinically significant (Sirgo et al
1985). Neither azathioprine nor interleukin-10 affect the pharmacokinetics of
prednisolone (Frey et al 1981, Chakraborty et al 1999). In addition, indomethacin
and naproxen have increased free prednisolone concentration by 30 to 60%
without affecting total prednisolone concentrations (Rae et al 1982). Oral
contraceptive steroids have increased the t½ of prednisolone about 1.5- to 2.5-
fold, and careful monitoring is recommended when oral contraceptives and
prednisolone are used concomitantly (Legler and Benet 1986).
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The CYP3A4 inhibitor ketoconazole (200 mg/day) has increased plasma
concentrations of prednisolone by about 50% following oral prednisone or
intravenous prednisolone administration (Zürcher et al 1989). Two other studies,
however, failed to find any effect with 200 mg/day ketoconazole on either the
pharmacokinetics or pharmacodynamics of prednisolone (Ludwig et al 1989,
Yamashita et al 1991). Furthermore, neither troleandomycin nor grapefruit juice
affected its pharmacokinetics (Szefler et al 1982, Hollander et al 1995). However,
administration of diltiazem increased the AUC of prednisolone by about 20%
after ingestion of prednisone (Imani et al 1999). Whether cyclosporin affects the
elimination of prednisolone is unclear. Two reports have suggested cyclosporin
inhibits the elimination of prednisolone (Öst 1984, Langhoff et al 1985). In
contrast, some investigators have found cyclosporin not to alter its metabolism
(Frey et al 1987, Rocci et al 1988).
2.8. Dexamethasone
Pharmacokinetics. Dexamethasone is rapibly absorbed after oral administration.
The Cmax of oral dexamethasone is reached between 1.2 and 2.7 h (Rose et al
1981b, Loew et al 1986, O’Sullivan et al 1997). Although mean absolute
bioavailability of dexamethasone has ranged from 61 to 78% (Duggan et al 1975,
Rose et al 1981b, O’Sullivan et al 1997), large interindividual variation in the
absolute bioavailability can exist ,e.g., from 51% to 89% in healthy volunteers
and from 34% to 79% in depressed patients (O’Sullivan et al 1997).
Dexamethasone is about 77% bound to plasma protein, mainly albumin, and it
appears neither to bind transcortin nor to compete with cortisol for its binding
protein (Peets et al 1969). Dexamethasone bound to albumin is unaffected by
increasing dexamethasone concentrations (Peets et al 1969). The mean Vd of
dexamethasone averages 0.58 to 1.5 l/kg (Rose et al 1981b, Workman et al 1986,
O’Sullivan et al 1997). Loew et al (1986) found the AUC of dexamethasone to
increase less than proportionally to dose after oral 0.5- to 1.5-mg doses. However,
no dose-dependency was observed when dexamethasone was administered to
healthy subjects at a 15-mg dose and at high 1.5 mg/kg doses or to cancer patients
at 40- to 200-mg doses (Rohdewald et al 1987, Brady et al 1987). The t½ of
dexamethasone averages 3.1 to 6.1 h and its Cl 110 to 180 ml/h/kg (Rose et al
1981b, O’Sullivan et al 1997).
Dexamethasone sodium phosphate is a prodrug. After intravenous administration,
the hydrolysis of the phosphate ester to dexamethasone is rapid, with half-life of 5
min, and the Cmax of dexamethasone is reached after 10 min (Rohdewald et al
1987). Conversion of dexamethasone phosphate to dexamethasone alcohol
appears to be about 90% (Hare et 1975).
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The 6β-hydroxylation is the major metabolic pathway of dexamethasone
(Minagawa et al 1986), and hydroxylation both at the 6α and at the 6β position
have shown to be CYP3A4-mediated in human liver microsomes in vitro (Gentile
et al 1996). About 9 to 10% of the dose was excreted as unchanged
dexamethasone in the urine (Duggan et al 1975, Miyabo et al 1981), with
glucuronides present in small amounts (Minagawa et al 1986, Tomlinson et al
1996). After an intravenous dose of labelled dexamethasone, about 64% was
excreted in the urine within 24 h, and unconjugated metabolites formed the
largest fraction, about 30% of the dose (Haque et al 1972).
The t½ of dexamethasone has been reported to be prolonged in liver disease and
shortened in chronic renal failure (Kawai et al 1985). However, Workman et al
(1986) found chronic renal failure not to affect the pharmacokinetics of
dexamethasone. The t½ of oral dexamethasone was longer in men than in women
(6.4 h vs. 4.8 h), and the gender difference appears to be weight-related
(O’Sullivan et al 1997). In addition, smoking did not affect the pharmacokinetics
of dexamethasone (Rose et al 1981b).
Pharmacokinetic drug interactions. Phenobarbital has increased the Cl of
dexamethasone by 88% and decreased its t½ by 44% (Brooks et al 1972).
Phenytoin increased the Cl and reduces the systemic bioavailability of
dexamethasone (Chalk 1984). Carbamazepine 800 mg daily raises the dose of
dexamethasone needed to suppress plasma cortisol 2- to 4-fold, when measured
as a part of the dexamethasone suppression test (Kobberling and v zur Muhlen
1973).
Treatment with ephedrine has decreased the t½ of dexamethasone by 36% and
increased its Cl by 42%, but theophylline appears not to interact with
dexamethasone (Brooks et al 1977). Cimetidine does not affect the
pharmacokinetics of intravenous dexamethasone (Peden et al 1984). There appear
to be no controlled studies concerning the pharmacokinetic interactions between
CYP3A4 inhibitors and dexamethasone in humans.
A summary of pharmacokinetic variables of methylprednisolone, prednisolone,
and dexamethasone is shown in Table IV.
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Synthetic glucocorticoids are widely used because of their anti-inflammatory and
immunosuppressive properties in many different types of formulations. This
study, however, will focus on systemic oral and/or intravenous glucocorticoids
methylprednisolone, prednisolone, and dexamethasone. It has been shown that
these glucocorticoids are eliminated mainly by metabolism, and CYP3A4 may
play a different role in their biotransformation. Many drugs currently on the
market are known to inhibit CYP3A4-mediated metabolism in vitro and in vivo.
CYP3A4 is also present in the gut, and inhibition of drug metabolism can occur
even in the intestinal mucosa, a fact which may be important in regard to orally
administered drugs.
Glucocorticoids have a very wide therapeutic margin, and high doses can be
given intravenously, e.g., in an emergency. However, for continuous use at doses
as low as possible, intermediate-acting glucocorticoids and alternate-day therapy
have been recommended to minimise the catabolic action and HPA-axis
suppression of glucocorticoids. Thus, pharmacokinetic interaction of
glucocorticoids with other drugs, resulting in an increased and prolonged
exposure to glucocorticoids, can be clinically important. Increased knowledge of
potential drug-drug interactions of systemic glucocorticoids would result in more
proper and safe use of these drugs.
The specific aims of this thesis were to study:
1. The effect of itraconazole on the pharmacokinetics and adrenal-suppressant
effect of oral and intravenous methylprednisolone (Studies I and II), with special
attention to the route of methylprednisolone administration.
2. The effect of itraconazole on the pharmacokinetics and adrenal-suppressant
effect of oral prednisolone (Study IV)
3. The effect of itraconazole on the pharmacokinetics and adrenal-suppressant
effect of oral and intravenous dexamethasone (Study VI), with special attention
to the route of dexamethasone administration.
4. The effect of diltiazem and mibefradil on the pharmacokinetics and adrenal-
suppressant effect of oral methylprednisolone (Study III)
5. The effect of grapefruit juice on the pharmacokinetics and adrenal-suppressant
effect of oral methylprednisolone (Study V).
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1. Ethical considerations
All study protocols were approved by independent Ethics Committee of the
Department of Clinical Pharmacology, University of Helsinki, and reviewed by the
National Agency of Medicines in Finland. Before entering the study all subjects
received both oral and written information and gave their written consent.
2. Study subjects
All subjects participating in Studies I to VI were healthy volunteers (age range 19-
42 years; weight 45-90 kg). Altogether 43 study subjects (25 females, 18 males)
participated in Studies I to IV. A total of ten subjects participated in more than one
study; seven subjects in two, two subjects in three and one subject in four times.
None of the subjects were smokers or used continuous medication, except that in
Studies I to III eight female subjects used oral contraceptive steroids. Use of other
drugs was prohibited starting 2 weeks before each study day. Furthermore,
participation in another trial and blood donation within one month before the study
period were exclusion criteria. Each subject underwent a medical screening 1 to 3
weeks before participation in a study. This screening included clinical
examination, medical history, and routine laboratory tests, and in Study III a
standard electrocardiogram (ECG) to ascertain that each was in good health.
3. Study protocol
3.1. Study design
In Studies I to IV and VI the subjects were pretreated with a potential enzyme
inhibitor or placebo and in Study V with double-strength grapefruit juice or water.
A randomised crossover design was used in two or three phases with a washout
period of 4 weeks. All studies were double-blind, except Study V, which was an
open study.
The pretreatment drugs and matched placebos were supplied, packed, and labelled
according to a randomisation list for each subject by the Pharmacy of the Helsinki
University Central Hospital. Pretreatment drugs and matched placebos were
identical in order to maintain the the double-blind nature of the studies. The study
drugs (glucocorticoids) were also supplied by the Pharmacy of the Helsinki
University Central Hospital. Glucocorticoids were given under the supervision of
the investigator in the morning at 9:00 after an overnight fast. The oral study drugs
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were ingested with 150 ml of water, except in Study V with 200 ml of water or
double-strength grapefruit juice. Consumption of grapefruit juice was prohibited,
except in Study V, and use of alcohol was not allowed during the study days and 2
days beforehand. A light standard meal was served at 2 and 10 h and lunch 6 h
afterwards. The structure of the studies is described below and in Table V.
Table V. Structure of Studies I-VI
Study Pretreatment Study drug/ Glucocorticoid
No. Subject Drug Daily dose Duratio
n
Drug, dose and
route
Timing
I n = 10 Itraconazole
Placebo
200 mg x 1 Days 1-4
Days 1-4
Methylprednisolone
16 mg orally
On day 4,
1 h after
pretreatment
II n = 9 Itraconazole
Placebo
200 mg x 1 Days 1-4
Days 1-4
Methylprednisolone
16 mg intravenously
as sodium succinate
On day 4,
1 h after
pretreatment
III n = 9 Diltiazem
Miberadil
Placebo
60 mg x 3
60 mg x 2
50 mg x 1
Days 1-2
Day 3
Days 1-3
Days 1-3
Methylprednisolone
16 mg orally
On day 3,
2 h after
morning
pretreatment
dose
IV n = 10 Itraconazole
Placebo
200 mg x 1 Days 1-4
Days 1-4
Prednisolone
20 mg orally
On day 4,
1 h after
pretreatment
V n = 10 Grapefruit
juice
Water
200 ml x 3 Days 1-3
Days 1-3
Methylprednisolone
16 mg orally
With 200 ml
grapefruit juice
in morning of
day 3
VI n = 8 Itraconazole
Placebo
200 mg x 1 Days 1-4
Days 1-4
Dexamethasone
4.5 mg orally
Dexamethasone
sodium phosphate
5.0 mg
intravenously
On day 4,
1 h after
pretreatment
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Study I. Ten subjects (7 females/3 males) each received 200 mg itraconazole or
placebo orally once daily for 4 days. On day 4, a dose of 16 mg
methylprednisolone was ingested at 9:00 a.m., one hour after the
itraconazole/placebo. Blood samples were drawn before the methylprednisolone
administration and ½, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 h later. Plasma was
separated within 30 min and stored at -40° C until analysis. Methylprednisolone,
cortisol, itraconazole, and hydroxyitraconazole concentrations were determined.
Study II. Nine subjects (4 females/5 males) each received 200 mg itraconazole or
placebo orally once daily for 4 days. On day 4, an intravenous dose of 16 mg
methylprednisolone as sodium succinate was given within 2 min at 9:00 a.m., one
hour after itraconazole/placebo. Blood samples were drawn before
methylprednisolone administration and 3 min and ½, 1, 2, 3, 4, 5, 6, 8, 10, 12, and
24 h later. The sampling tubes were immediately placed into ice water, and plasma
was separated within 30 min by centrifugation at +4°C. The samples were stored at
-80°C until analysis. Methylprednisolone, cortisol, itraconazole, and
hydroxyitraconazole concentrations were determined.
Study III. Nine subjects (8 females/1 male) each received 60 mg diltiazem 3 times
a day (at 7:00 a.m., 3:00 p.m., and 9:00 p.m.), 50 mg mibefradil once a day (at 7:00
a.m. and corresponding placebo at 3:00 p.m. and 9:00 p.m.), or placebo three times
a day, all of these orally and all for 2 days. On the next day (day 3), only two
pretreatment doses were given (at 7:00 a.m. and 3:00 p.m), and a dose of 16 mg
methylprednisolone was ingested at 9:00 a.m., 2 h after diltiazem, mibefradil, or
placebo. Blood samples were drawn before methylprednisolone administration and
at ½, 1, 1½, 2, 3, 4, 5, 6, 8, 10, 12, 23, and 47 h. Plasma was separated within 30
min and stored at -80° C until analysis. Methylprednisolone, cortisol, diltiazem,
and mibefradil concentrations were determined. Each subject underwent a
screening including ECG, blood pressure, and heart rate on the first and third day
of each study period.
Study IV. Ten subjects (5 females/5 males) each received 200 mg itraconazole or
placebo orally once daily for 4 days. On day 4, a dose of 20 mg prednisolone was
ingested at 9:00 a.m., one h after itraconazole/placebo. Blood samples were drawn
before prednisolone administration and at ½, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 23, and
47 h. Plasma was separated within 30 min and stored at -40 °C until analysis.
Prednisolone, cortisol, itraconazole, and hydroxyitraconazole concentrations were
determined.
Study V. Ten subjects (2 females/8 males) each drank 200 ml double-strength
grapefruit juice or 200 ml water 3 times a day for 2 days. On day 3, a dose of 16
mg methylprednisolone was ingested at 9:00 a.m. with 200 ml double-strength
grapefruit juice or water. In addition, 200 ml grapefruit juice or water was given ½
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and 1½ h after methylprednisolone administration. Blood samples were drawn
before methylprednisolone administration and at ½, 1, 1½, 2, 3, 4, 5, 6, 8, 10, 12,
23, and 47 h. Plasma was separated within 30 min and stored at -40 °C until
analysis. Methylprednisolone and cortisol concentrations were determined.
Study VI. Eight subjects (7 females/1 male) each ingested either 200 mg
itraconazole (during 2 phases) or placebo (during 2 phases) once daily for 4 days.
On the fourth day, at 9:00 a.m., one h after itraconazole/placebo, each subject
received 4.5 mg dexamethasone orally or a dose of 5.0 mg dexamethasone sodium
phosphate (corresponds to 3.85 mg dexamethasone) intravenously during both the
itraconazole and placebo phases. Dexamethasone sodium phosphate was given as
an intravenous injection over 2 min. Blood samples were drawn before
dexamethasone administration and at 1, 2, 3, 4, 6, 8, 10, 12, 23, 47, and 71 h. After
intravenous administration, an additional sample was drawn 0.25 h after
dexamethasone injection. Plasma was separated within 30 min and stored at -70°C
until analysis. Dexamethasone, cortisol, itraconazole, and hydroxyitraconazole
concentrations were determined.
3.2. Determination of plasma drug and cortisol concentrations
All plasma drug and cortisol concentrations were determined in the Analytical
Laboratory of the Department of Clinical Pharmacology, University of Helsinki.
Methylprednisolone. In Studies I, II, and III, plasma methylprednisolone
concentrations were determined by high-performance liquid chromatography
(HPLC) with ultraviolet detection (Ebling et al 1984, Kong et al 1988).
Dexamethasone served as the internal standard. The quantification limit was 3
ng/ml in Studies I and II and 2 ng/ml in Study III. The interday coefficient of
variation (CV) for methylprednisolone ranged from 5.8% to 11.9% at < 20 ng/ml
concentrations and 1.2% to 4.9% at higher methylprednisolone concentrations.
In Study V, the plasma methylprednisolone concentrations were determined by
liquid chromatography-ionspray-tandem mass spectrometry with use of the PE
SCIEX API 3000 LC/MS/MS system (Sciex Division of MDS Inc, Toronto,
Canada) (Kong et al 1988, Dodds et al 1997). Dexamethasone served as the
internal standard. The quantification limit was 0.5 ng/ml and the interday CV 6.3%
at 4.3 ng/ml, 2.3% at 25 ng/ml, and 3.6% at 118 ng/ml (n = 4 at all concentrations).
Prednisolone. Plasma prednisolone concentrations were determined by HPLC
with ultraviolet detection (McWhinney et al 1996). Dexamethasone served as the
internal standard. The quantification limit was 5 ng/ml and the interday CV 8.5%
at 11 ng/ml, 2.8% at 49 ng/ml, and 3.8% at 227 ng/ml (n = 6 at all concentrations).
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Dexamethasone. Plasma dexamethasone concentrations were determined by
HPLC with ultraviolet detection (McWhinney et al 1996). Methylprednisolone
served as the internal standard. The quantification limit was 2 ng/ml and the
interday CV 9.0% at 3.7 ng/ml (n = 11), 1.6% at 36 ng/ml (n = 14), and 2.2% at
158 ng/ml (n = 14).
Itraconazole and hydroxyitraconazole. Itraconazole and hydroxyitraconazole
plasma concentrations were determined by HPLC with fluorescence detection
(Allenmark et al 1990, Remmel et al 1988). R51012 (Janssen Pharma, Beerse,
Belgium) served as the internal standard. The quantification limit was 10 ng/ml for
both compounds. The interday CV for itraconazole ranged from 0.5% to 5.6% and
that for hydroxyitraconazole from 0.7% to 9.3% at relevant itraconazole
concentrations.
Diltiazem. Plasma diltiazem concentrations were determined by HPLC with
ultraviolet detection (Dube et al 1988, Hynning et al 1988). Verapamil served as
the internal standard. The quantification limit was 10 ng/ml, and the interday CV
for diltiazem was 4.0% at 24.7 ng/ml (n = 6) and 3.4% at 232 ng/ml (n = 6).
Mibefradil. Plasma mibefradil concentrations were determined by HPLC
(Skerjanec and Tam 1995) with fluorescence detection. An external standard
served in this assay. The quantification limit was 10 ng/ml. The intraday CV for
mibefradil was 1.5% at 15.8 ng/ml (n = 10) and 2.0% at 50.9 ng/ml (n = 10).
Cortisol. In Studies I to IV and VI plasma cortisol concentrations were determined
by HPLC with ultraviolet detection (Ebling et al 1984, Kong et al 1988,
McWhinney et al 1996). Dexamethasone served as the internal standard. The
quantification limit was 3 ng/ml in Studies I and II, 2 ng/ml in III and IV, and 5
ng/ml in VI. The interday CV for cortisol ranged from 3.7% to 14.5% at < 20
ng/ml concentrations and from 1.6% to 6.5% at higher cortisol concentrations.
In Study V, the plasma cortisol concentrations were determined by liquid
chromatography-ionspray-tandem mass spectrometry with use of the PE SCIEX
API 3000 LC/MS/MS system (Sciex) with dexamethasone as the internal standard.
The quantification limit was 0.5 ng/ml. The interday CV was 1.2% at 4.1 ng/ml,
6.1% at 25 ng/ml, and 4.3% at 123 ng/ml (n = 5 at all concentrations).
3.3. Pharmacokinetic calculations
The peak concentration in plasma (Cmax) and time to Cmax (tmax) were obtained
directly from the data. The elimination rate constant (kel) was determined for
calculation of elimination half-life (t½) and total area under the plasma
concentration-time curve [AUC(0-∞)]. The terminal log-linear phase of the plasma
concentration-time curve was visually identified for each subject. The elimination
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rate constant (kel) was calculated by regression analysis of this log-linear part of the
plasma concentration-time curve. The t½ was calculated from the equation
t½ = ln2 / kel
The area under the plasma concentration-time curve (AUC) values were calculated
by use of the linear trapezoidal rule (Studies I, II and IV) or by log trapezoidal rule
(Studies III, V, and VI). To determine the AUC to infinity, the extrapolation to
infinity was done by dividing the last measured concentration by the corresponding
kel value. AUC values were calculated, referring to the time from 0 to 24 h after the
administration of the study drug in Study I. Furthermore, AUC values from 12 to
24 h (Study II), from 12 to 23 h (Studies III and VI), and from 23 to 47 h (Study
VI) were calculated as a posthoc analysis of AUC. Plasma concentrations for
calculation of the AUC(12-24), AUC(12-23), and AUC(23-47) values were
estimated with use of kel values when the concentrations were below the
quantification limit. Furthermore, for itraconazole, diltiazem, and mibefradil, the
AUC values [AUC(0-24) or AUC(0-23)] after administration of the study drug
were calculated by linear trapezoidal rule.
In Studies II and VI, after intravenous administration of methylprednisolone and
dexamethasone the systemic clearance (Cl) and volume of distribution (Vd) were
calculated from the equations
Cl = Dose / AUC(0-∞)
Vd = Cl / kel
In Study VI the bioavailability of oral dexamethasone (F) was calculated (Gibaldi
and Perreir 1982) from the equation
F = [AUC(0-∞)po·Doseiv] / [AUC(0-∞)iv·Dosepo]
For the pharmacokinetic calculations, the conversion of intravenous
dexamethasone sodium phosphate to dexamethasone alcohol was expected to be
90% (Hare et al 1975). The pharmacokinetic program, MK model, version 5
(Biosoft, Cambridge, UK) were used for calculation of the pharmacokinetic
parameters.
3.4. Pharmacodynamic measurements
In all studies, endogenous cortisol secretion and the adrenal-suppressant effect of
glucocorticoids were evaluated by measuring morning plasma cortisol
concentrations before the administration of the glucocorticoid and in the morning
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at 23 or 24, 47, and 71 h after glucocorticoid administration. In addition, in Studies
III and V, the AUC of cortisol from 0 to 12 h after methylprednisolone
administration [AUC(0-12)] was calculated by use of the linear trapezoidal rule.
3.5. Statistical methods
All individual subject data, medical history, results from the clinical examination,
chemical laboratory tests, ECG, and plasma drug and cortisol concentrations are
considered as source data. The individual data were recorded into a database.
However, plasma drug and cortisol concentrations were sent as an electronic
database.
Results are expressed as mean values with standard deviation (SD) and as mean
values with standard error of mean (SEM) in figures. Each tmax value is presented
as median with range. The pharmacokinetic variables and the 0-, 23- or 24-, 47-,
and 71-hour plasma cortisol concentrations between the phases were compared
with Student’s 2-tailed t-test for paired data. In Study III, the statistical analysis
was done with two-way analysis of variance (ANOVA) with the Tukey test. In all
studies, the Wilcoxon test was used for analysis of tmax. The 95% confidence
intervals (CI) and ranges were presented for selected variables.
Pearson’s correlation coefficient was used to evaluate the linear correlations.
Spearman rank-order correlation coefficient was used to investigate the possible
relationship between the morning plasma cortisol concentration and the AUC(12-
23) and AUC(0-∞) of methylprednisolone (Study III). In Study VI, nonlinear
regression was used to evaluate the relationship between the AUC(23-47) of
dexamethasone and morning plasma cortisol concentrations at 47 and 71 h.
In all studies, the level of statistical significance was p <0.05. The number of
subjects in each study was 8-10, which was considered to be sufficient in a
pharmacokinetic cross-over study to discover an about 30 to 50% change in the
AUCs, sufficient large to be clinically significant. The statistical analyses were
done with the statistical program Systat for Windows, version 6.0.1 (SPSS Inc.,
Chicago, Il, USA).
3.6. Archiving
All study-related documents, e.g., protocols, original signed informed consents,
source data are archived at the Department of Clinical Pharmacology, University of
Helsinki.
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RESULTS
1. Interaction between itraconazole and glucocorticoids
1.1. Oral methylprednisolone (Study I)
Itraconazole 200 mg daily for 4 days markedly increased plasma concentrations
of oral methylprednisolone. Itraconazole increased the AUC(0-) of
methylprednisolone 3.9-fold (p <0.001) and the Cmax 1.9-fold: from 118 (25)
ng/ml to 221 (49) ng/ml; p <0.001, and prolonged the t½ of methylprednisolone
from 1.9 (0.3) h to 4.4 (0.7) h (p <0.001), compared with placebo (Figures 5 and
11). The tmax of methylprednisolone was not significantly affected by
itraconazole.
The mean morning plasma cortisol concentration, measured 24 h after the
ingestion of 16 mg methylprednisolone, was, during the itraconazole phase,
about 13% of that during the placebo phase: 18 (23) ng/ml versus 139 (60)
ng/ml; p <0.001; Figure 6. No significant difference existed in the morning
plasma cortisol concentration between the itraconazole and placebo phases just
before ingestion of methylprednisolone.
Figure 5. Pharmacokinetic changes of methylprednisolone. Mean relative changes (with
ranges) in pharmacokinetic variables of oral and intravenous methylprednisolone after
itraconazole compared with placebo pretreatment (= 100%; indicated with a dashed line).
AUC, area under the plasma concentration-time curve; T½, elimination half-life; Cmax, peak
plasma concentration; Cl, systemic clearance; Vd, volume of distribution
** p <0.001 compared with placebo phase
* p <0.01 compared with placebo phase
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1.2. Intravenous methylprednisolone (Study II)
Itraconazole 200 mg daily for 4 days increased the AUC(0-) of intravenous
methylprednisolone 2.6-fold (p <0.001) and the AUC(12-24) 12.2-fold (range,
6.7-fold to 29.3-fold; p <0.001). Itraconazole decreased the Cl of
methylprednisolone by 60%: 167 (51) ml/h/kg versus 449 (237) ml/h/kg; p <
0.01. The t½ of methylprednisolone was increased from 2.1 (0.3) h to 4.8 (0.8) h
(p <0.001) by itraconazole (Figures 5 and 11). The Vd of methylprednisolone was
unaffected by itraconazole (Figure 5).
The mean morning plasma cortisol concentration measured 24 h after the
ingestion of 16 mg methylprednisolone was during the itraconazole phase 9% of
that during the placebo phase: 11 (9.0) ng/ml versus 117 (50) ng/ml; p <0.001;
Figure 6. No significant difference existed in morning plasma cortisol
concentration between the itraconazole and placebo phases just before ingestion
of methylprednisolone.
Figure 6. Mean (with SD) plasma cortisol concentrations, measured 24 hours after
oral and intravenous (Iv) methylprednisolone during placebo and itraconazole
phases.
** p <0.001 compared with placebo phase
RESULTS
48
1.3. Oral prednisolone (Study IV)
Itraconazole 200 mg daily for 4 days slightly increased the AUC(0-∞) of
prednisolone by 24% (p <0.001), and the t½ by 29%: 3.6 (0.4) h versus 2.8 (0.4)
h; p <0.001, compared with placebo (Figures 7 and 11). The Cmax and tmax of
prednisolone were not significantly affected by itraconazole (Figure 7).
The mean morning plasma cortisol concentration, measured 23 h after the
ingestion of 20 mg prednisolone, was during the itraconazole phase about 73% of
that during the placebo phase: 104 (39) ng/ml versus 141 (33) ng/ml; p <0.001;
Figure 8. No significant difference existed in morning plasma cortisol
concentration between the itraconazole and placebo phases just before ingestion
of prednisolone or 47 h after it.
Figure 7. Pharmacokinetic changes of prednisolone. Mean relative changes (with
ranges) in pharmacokinetic variables of oral prednisolone after itraconazole
compared with placebo pretreatment (= 100%; indicated with a dashed line).
AUC, area under the plasma concentration-time curve; T½, elimination half-life; Cmax, peak
plasma concentration
** p <0.001 compared with placebo phase
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Figure 8. Mean (with SD) plasma cortisol concentrations, measured 23 hours after
oral prednisolone during placebo and itraconazole phases.
** p <0.001 compared with placebo phase
1.4. Oral and intravenous dexamethasone (Study VI)
Itraconazole 200 mg daily for 4 days markedly increased the AUC(0-),
AUC(12-23), and AUC(23-47) of oral dexamethasone 3.7-fold (p <0.001), 8.2-
fold (p <0.001), and 46-fold (p <0.001), respectively, compared with placebo
(Figures 9 and 11). The Cmax of oral dexamethasone was increased 1.7-fold: 60
(17) ng/ml versus 38 (16) ng/ml; p <0.001 and t½ 2.8-fold: 10.9 (2.0) h versus 4.0
(0.9) h; p <0.001, by itraconazole (Figures 9 and 11). The absolute bioavailability
of oral dexamethasone rose from 75 (9)% during the placebo phase to 86 (11)%
during the itraconazole phase (p =0.13).
Itraconazole 200 mg daily for four days increased the AUC(0-), AUC(12-23),
and AUC(23-47) of intravenous dexamethasone 3.3-fold (p <0.001), 9.1-fold (p
<0.001), and 74-fold (p <0.001), respectively, compared to placebo (Figures 9
and 11). The Cl of dexamethasone was decreased by 68% (p <0.001), and the t½
was increased 3.2-fold: 12.2 (2.3) h versus 4.1 (1.4) h; p <0.001), by itraconazole
(Figures 9 and 11). The Vd was unaffected by itraconazole (Figure 9).
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Mean morning plasma cortisol concentrations, measured 47 and 71 h after
administration of dexamethasone, were lower after exposure to itraconazole than
to placebo: 47 h after oral dexamethasone, 6.4 (2.1) ng/ml versus 134 (39) ng/ml;
p <0.001 and 71 h after oral dexamethasone, 42 (37) ng/ml versus 164 (50)
ng/ml; p <0.001; Figure 10. Additionally, 47 h after intravenous dexamethasone,
6.8 (2.9) ng/ml versus 130 (40) ng/ml; p <0.001 and 71 h after intravenous
dexamethasone, 35 (27) ng/ml versus 174 (40) ng/ml; p <0.001; Figure 10.
Figure 9. Pharmacokinetic changes of dexamethasone. Mean relative changes (with
ranges) in pharmacokinetic variables of oral and intravenous dexamethasone after
itraconazole compared with placebo pretreatment (= 100%; indicated with a dashed
line).
   AUC, area under the plasma concentration-time curve; T½, elimination half-life; Cmax,
   peak plasma concentration; Cl, systemic clearance; Vd, volume of distribution
   ** p <0.001 compared with placebo phase
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However, no significant difference appeared in morning plasma cortisol
concentration between the itraconazole and placebo phases just before or 23 h
after administration of either intravenous or oral dexamethasone. Very good
exponential relationships existed between the AUC(23-47) of dexamethasone
and the morning cortisol concentrations at 47 h (r =0.960) and 71 h (r =0.912)
after intravenous and at 47 h (r =0.953) and 71 h (r =0.874) after oral
dexamethasone.
Figure 10. Mean (with SD) plasma cortisol concentrations, measured 23, 47, and 71
hours after oral and intravenous dexamethasone during placebo and itraconazole
phases.
** p <0.001 compared with placebo phase
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Figure 11. Mean relative changes (with ranges) in AUC (upper panel) and t½ values
(lower panel) of different glucocorticoids after itraconazole compared with placebo
pretreatment (= 100%; indicated with a dashed line).
Mepre = methylprednisolone, Pred = prednisolone, Dexa = dexamethasone, iv = intravenous
AUC, area under the plasma concentration-time curve; T½, elimination half-life
** p <0.001 compared with placebo phase
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2. Interaction between diltiazem or mibefradil and oral
methylprednisolone (Study III)
Compared with placebo, diltiazem and mibefradil increased the AUC(0-∞) of
oral methylprednisolone 2.6-fold (p <0.001) and 3.8-fold (p <0.001), and the
Cmax 1.6-fold (p <0.001) and 1.8-fold (p <0.001), respectively (Figure 12).
Furthermore, diltiazem and mibefradil increased the t½ of methylprednisolone
1.9-fold (p <0.001) and 2.7-fold (p <0.001), respectively (Figure 12). Compared
with placebo, the AUC(12-23) of methylprednisolone was increased 28.2-fold (p
<0.01) by diltiazem and 72.1-fold (p <0.001) by mibefradil. The tmax of
methylprednisolone was not significantly altered by diltiazem, but mibefradil
increased the tmax of methylprednisolone from 1.5 to 3.0 h (p <0.05) compared
with placebo. Mibefradil increased the AUC(0-) and AUC(12-23) of
methylprednisolone more than did diltiazem (p <0.001).
Figure 12. Pharmacokinetic changes of methylprednisolone. Mean relative changes
(with ranges) in pharmacokinetic variables of oral methylprednisolone after
diltiazem (Dilt) and mibefradil (Mibe) compared with placebo pretreatment (=
100%; indicated with a dashed line).
AUC, area under the plasma concentration-time curve; T½, elimination half-life; Cmax, peak
plasma concentration
** p <0.001 compared with placebo phase
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The morning plasma cortisol concentration, measured 23 h after ingestion of 16
mg methylprednisolone, was substantially lower after exposure to diltiazem and
mibefradil than to placebo: 22 (16) ng/ml and 4.2 (1.6) ng/ml, respectively,
versus 186 (80) ng/ml; p <0.001; Figure 13. Furthermore, a significant negative
correlation appeared between the morning plasma cortisol concentration and the
AUC(12-23) (r = -0.81; p <0.001) and the AUC(0-∞) (r = -0.76; p <0.001) of
methylprednisolone. However, no significant differences existed in the AUC(0-
12) of cortisol between the phases or in the morning plasma cortisol
concentrations just before ingestion of methylprednisolone or 47 h afterwards
(Figure 13).
Figure 13. Mean (with SD) plasma cortisol concentrations, measured 23 and 47
hours after oral methylprednisolone during placebo, diltiazem, and mibefradil
phases.
** p <0.001 compared with placebo phase
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3. Interaction between grapefruit juice and oral
methylprednisolone (Study V)
Grapefruit juice increased the AUC(0-∞) of oral methylprednisolone by 75% (p
<0.001), the Cmax by 27% (p <0.01), and the t½ by 35%: 2.8 (0.3) h versus 2.1
(0.5) h; p <0.001, compared with water (Figure 14). The tmax of
methylprednisolone was prolonged from 2.0 to 3.0 h (p < 0.05) by grapefruit
juice.
Figure 14. Pharmacokinetic changes of methylprednisolone.
Mean relative changes (with ranges) in pharmacokinetic variables of orally
administered methylprednisolone during grapefruit juice phase compared with water
phase (= 100%; indicated with a dashed line).
AUC, area under the plasma concentration-time curve; T½, elimination half-life; Cmax, peak
plasma concentration
** p <0.001 compared with placebo phase
* p <0.01 compared with placebo phase
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The morning plasma cortisol, measured 23 h after the administration of 16 mg
methylprednisolone, was slightly lower during the grapefruit juice phase than
during the water phase :133 (43) ng/ml versus 149 (39) ng/ml; p =0.09; Figure
15]. The AUC(0-12) of cortisol was slightly greater during the grapefruit juice
phase than during the water phase: 500 (165) ng  h/ml versus 453 (103) ng 
h/ml; p =0.08. On the other hand, the plasma cortisol concentration, measured in
the morning before administration of methylprednisolone, was lower during the
grapefruit juice phase than during the water phase: 140 (47) ng/ml versus 169
(37) ng/ml; p <0.05.
Figure 15. Mean (with SD) plasma cortisol concentrations, measured 23 hours after
oral methylprednisolone during grapefruit juice (GFJ) and water phases.
# p =0.09 compared with water phase
DISCUSSION
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DISCUSSION
1. Methodological considerations
The present study evaluated the effect of CYP3A4 inhibitors on synthetic
glucocorticoids after their systemic administration. In addition to
methylprednisolone, prednisolone, and dexamethasone, also betamethasone and
prednisone are in clinical use in Finland. Betamethasone and prednisone were not
evaluated in the present study. Prednisone, however, is considered a prodrug and
is further metabolised to prednisolone.
All studies were carried out in healthy subjects, and after their pretreatment with
CYP3A4 inhibitor, a single dose of glucocorticoid was administered. This should
be considered in the extrapolation of the pharmacokinetic and pharmacodynamic
results to the patient using systemic glucocorticoids as a long-term treatment of
chronic disease. The doses of 20 mg prednisolone and of 16 mg
methylprednisolone used in the present study are equivalent regarding their
potency to glucocorticoid activity (Table III, page 26). However, an equivalent
dose of dexamethasone would be 3.0 mg. Thus, dexamethasone was used at higher
(3.85 mg and 4.5 mg) doses regarding the potency than were methylprednisolone
and prednisolone.
The susceptibility of glucocorticoids to interact with CYP3A4 inhibitors was
studied with potential CYP3A4 inhibitors currently on the market and in clinical
use. Mibefradil was, however, withdrawn from the market in 1998 during the
clinical phase of Study III. Each subject received oral and written information and
gave additional written consent.
The CYP3A4-enzyme inhibitors of the present study possess different inhibitory
mechanisms. Itraconazole, for example, is a competitive inhibitor of CYP3A4, and
grapefruit juice and maybe also mibefradil are non-competitive mechanism-based
inactivators of CYP3A4 (Back and Tjia 1991, Lown et al 1997, Prueksaritanont el
al 1999). The pretreatment period ranged from 3 to 4 days, because even such a
short treatment is sufficient to reveal a clinically significant inhibition of
CYP3A4. The t½ of mibefradil ranges from 10 h to 38 h, and it may be suggested
that the steady-state concentration was not reached during the 3-day treatment. In
addition, diltiazem has been shown dose-dependently to increase the plasma
concentrations of nifedipine (Tateishi et al 1989). Because the steady-state
concentration of the CYP3A4 inhibitors was perhups not reached during the 3 to 4
days, the interactions observed may become even more pronounced after
pretreatment for longer period or with a higher dose.
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The adrenal-suppressant effect of glucocorticoids was evaluated by measuring
morning plasma cortisol concentrations. The normal range for the morning plasma
cortisol concentration taken between 8:00 a.m. and 10:00 a.m. varies between 50
and 250 ng/ml according to the laboratory of Helsinki University Central Hospital.
In the present study blood samples for plasma cortisol determination were taken at
8:00 a.m. or at 9:00 a.m.. Cortisol secretion is pulsatile and exhibits a diurnal
pattern with the highest concentration occurring early in the morning. Morning
cortisol measurement has been used as an index of adrenal function, because it
reflects the peak endogenous activation of the HPA-axis (Grinspoon and Biller
1994). According to Grinspoon and Biller (1994), patients with a morning cortisol
concentration above 190 ng/ml do not need further testing for adrenal
insufficiency; although a low morning cortisol concentration may reflect the nadir
between pulses of cortisol secretion, a cortisol concentration of less than 30 ng/ml
is considered diagnostic for adrenal insufficiency. In the present series of
interaction studies, cortisol concentrations were not measured during the night-
time, which could have provided additional information.
2. Interaction between CYP3A4 inhibitors and
glucocorticoids
2.1. Methylprednisolone
Itraconazole markedly affected the pharmacokinetics both of oral and of
intravenous methylprednisolone. Itraconazole increased the AUC of oral
methylprednisolone 3.9- fold, the AUC of intravenous methylprednisolone 2.6-
fold, and decreased the Cl of methylprednisolone by 60%. The effect of
itraconazole on the AUC of methylprednisolone was about 50% greater after oral
than after intravenous administration. This finding can be explained by the
inhibition of the first-pass metabolism after oral administration, resulting in
increased bioavailability of methylprednisolone. This absolute bioavailability,
however, could not be calculated, because the effects of itraconazole on the oral
and intravenous methylprednisolone were evaluated in separate studies.
Diltiazem and mibefradil significantly affected the pharmacokinetics of oral
methylprednisolone. The extent to which mibefradil affected the pharmacokinetics
of oral methylprednisolone was as great as that seen after itraconazole in Study I.
This finding is in good agreement with that of an in vitro study in which
mibefradil was as potent inhibitor of CYP3A4 as was itraconazole (Wang et al
1999). Thus, these in vitro results predicted well the interactions observed in vivo
in the present studies. Furthermore, the effect of diltiazem on the
pharmacokinetics of methylprednisolone was smaller than that of mibefradil.
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However, in some subjects diltiazem affected the AUC of methylprednisolone as
almost as greatly as mibefradil.
Troleandomycin, a potent inhibitor of CYP3A4, has shown to decrease the Cl of
methylprednisolone by 64% (Szefler et al 1980). Furthermore, ketoconazole,
which is an even more potent inhibitor of CYP3A4 in vitro than is itraconazole,
increased the AUC of methylprednisolone about 2.4-fold and decreased its Cl by
66% (Glynn et al 1986). Erythromycin decreased the Cl of methylprednisolone by
46%, and in a recent study, clarithromycin reduced the apparent oral Cl of
methylprednisolone by 65% (LaForce et al 1983, Fost et al 1999). In summary, our
results for itraconazole, diltiazem, and mibefradil are in concordance with those of
previous studies on the effect of other potent CYP3A4 inhibitors on the
pharmacokinetics of methylprednisolone. Furthermore, in a congress report,
itraconazole for 4 days increased the AUC of oral methylprednisolone (48 mg)
about 2.5-fold, confirming the results of the present study (Lebrun-Vignes et al
1998).
In this study, high amounts of grapefruit juice increased the AUC of oral
methylprednisolone by 75%. Because grapefruit juice reduced intestinal CYP3A4
without affecting hepatic CYP3A4 activity (Lown et al 1997), it may be suggested
that the increase in AUC of oral methylprednisolone mainly resulted from
inhibition of its first-pass metabolism. However, recent studies have shown high
and repeated consumption of grapefruit juice to increase also the t½ of such drugs
as oral buspirone and cisapride (Lilja et al 1998b, Kivistö et al 1999). In the
present study, grapefruit juice slightly but significantly increased the t½ of oral
methylprednisolone, suggesting that it inhibited also systemic (hepatic) CYP3A4-
mediated methylprednisolone metabolism. Grapefruit juice alters the
pharmacokinetics of methylprednisolone considerably less than that of drugs such
as simvastatin, lovastatin, and buspirone (Lilja et al 1998a, Kantola et al 1998b,
Lilja et al 1998b). This may be because of the rather small first-pass metabolism
of methylprednisolone compared to that of simvastatin, lovastatin, and buspirone.
The increased and prolonged exposure to methylprednisolone during the
itraconazole, the diltiazem, and the mibefradil phases was associated with much
lower morning plasma cortisol concentrations at 23/24 h than those seen during
the placebo phase. Thus, concomitant use of methylprednisolone with itraconazole
or with these calcium-channel blockers enhances the adrenal-suppressant effect of
methylprednisolone by completely suppressing the peak cortisol concentration
seen in the placebo phase.
The concentration-effect relationship is log-linear, and despite the fact that
itraconazole increased the AUC of methylprednisolone by some 50% more after
oral than after intravenous administration, the extent of adrenal-suppressant effect
during the itraconazole phases was about the same. Furthermore, a negative
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correlation appeared between the night-time exposure to methylprednisolone
[AUC(12-23)] and the morning plasma cortisol concentrations (Study III). It is
known that endogenous cortisol is secreted almost immediately after synthesis
(Berne and Levy 1998). Therefore, increases in t½ and the night-time
concentrations of methylprednisolone may effectively suppress the peak cortisol
concentrations occurring early in the morning.
It can be concluded that these interactions between itraconazole, diltiazem, or
mibefradil and methylprednisolone are clinically significant and enhance the
adrenal-suppressant and perhups also other effects of methylprednisolone. In the
present study, the adrenal-suppressant effect of methylprednisolone tended to
increase during the grapefruit juice phase compared with that of the water phase.
Despite the statistically significant increase in the AUC, Cmax, and t½ of oral
methylprednisolone caused by grapefruit juice, the clinical significance of this
interaction appears to be minor. However, it might enhance the effects of
methylprednisolone in a few subjects.
2.2. Prednisolone
Despite the statistically significant increase in the AUC and t½ of oral
prednisolone caused by itraconazole, the interaction was quantitatively minor and
is probably of limited clinical significance. This observation is in agreement with
earlier findings that prednisolone does not significantly interact with
troleandomycin, ketoconazole, or clarithromycin, all potent inhibitors of CYP3A4
(Szefler et al 1982, Ludwig et al 1989, Yamashita et al 1991, Frost et al 1999). In
addition, the pharmacodynamics of prednisolone, evaluated by its suppressive
effects on serum cortisol, blood basophil, and helper T-lymphocyte values, were
not affected during the ketoconazole phase (Ludwig et al 1989, Yamashita et al
1991). In the present study, the adrenal-suppressant effect slightly increased
during the itraconazole phase compared with that of the placebo phase. The
clinical significance of this change is probably minor.
However, in contrast to other reports, Zürcher et al (1989) found ketoconazole to
raised prednisolone plasma concentration by 50% after both oral prednisone and
intravenous prednisolone, and Imani et al (1999) reported diltiazem to raise the
AUC of prednisolone slightly, by about 20%, after prednisone administration.
Imani et al (1999) suggested that diltiazem may in some patients enhance the
effects of prednisone. Furthermore, Zürcher et al (1989) suggested that the enzyme
responsible for the interconversion of prednisolone ↔ prednisone was unaffected
by ketoconazole. It may be assumed that the effect of itraconazole, another azole
antimycotic agent and potent inhibitor of CYP3A4, on plasma concentrations of
prednisolone is also similar after both prednisolone and prednisone administration.
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A congress report by Lebrun-Vignes et al (1998) confirms that itraconazole for
four days does not affect the pharmacokinetics prednisolone after oral prednisone
(60 mg).
In conclusion, the results of the present study strongly suggest that CYP3A4 does
not play a major role in the metabolic pathways of prednisolone. The concomitant
use of prednisolone or prednisone with itraconazole or with other potent CYP3A4
inhibitors should not markedly alter the effects of these glucocorticoids.
2.3. Dexamethasone
Itraconazole greatly affected the pharmacokinetics both of oral and of intravenous
dexamethasone. Itraconazole increased the AUC of oral dexamethasone 3.7-fold,
the AUC of intravenous dexamethasone 3.3-fold, and decreased the Cl of
dexamethasone by 68%. The effect of itraconazole on the AUC of dexamethasone
was similar after oral and after intravenous administration. Furthermore, the
absolute bioavailability of oral dexamethasone was slightly elevated, from 75% to
86%, by itraconazole. It is known that a significant increase in the AUC by
enzyme inhibition both after oral and after intravenous administration together
with small change in the absolute bioavailability are typical of a drug with low
hepatic clearance (Lin and Lu 1998).
The extent of itraconazole-dexamethasone interaction was approximately as great
as the extent of itraconazole-methylprednisolone interaction. Thus, the
susceptibility of dexamethasone and of methylprednisolone to interact with
itraconazole is similar. There seem to be no previous studies on the effects of
CYP3A4 inhibitors on the pharmacokinetics of oral and intravenous
dexamethasone. However, CYP3A4 has been shown to be important in
metabolism of dexamethasone in vitro (Gentile et al 1996). The present results
strongly suggest that this is the case also in vivo in human beings.
The increased exposure to dexamethasone during the itraconazole phases was
associated with much reduced morning plasma cortisol concentrations at 47 and
71 h than those during the placebo phases. The extent of the adrenal-suppressant
effect of dexamethasone during the itraconazole phase was about the same,
regardless of the route of dexamethasone administration.
In conclusion, concomitant use of itraconazole or probably also other potent
CYP3A4 inhibitors woth dexamethasone greatly enhances the adrenal-suppressant
and perhaps also other effects of dexamethasone.
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3. General discussion
Itraconazole, diltiazem, and mibefradil are known to inhibit CYP3A4-mediated
drug metabolism. Therefore, it can be assumed that inhibition of CYP3A4-
mediated metabolism during first-pass and elimination phases is the most probable
mechanism explaining the observed interactions in the present study. However,
itraconazole, diltiazem, and mibefradil are also inhibitors of P-gp (Miyama et al
1998, Cornwell et al 1987, Wandel et al 2000). In addition, grapefruit juice has
been demonstrated to inhibit the vinblastine cellular efflux by P-gp and to
modulate to a limited extent P-gp mediated transport of saquinavir in vitro
(Takanaga et al 1998, Eagling et al 1999). Eagling et al (1997) suggest, however,
that the in vivo effects of grapefruit juice most likely result from inhibition of
CYP3A4 and only to a minor extent from modulation of P-gp. In contrast to
prednisolone (Saitoh et al 1998), methylprednisolone and dexamethasone have
been shown to be substrates for P-gp (Saitoh et al 1998, Ueda et al 1992);
therefore, inhibition of this transmembrane efflux pump may have contributed to
the observed interactions. However, present studies do not allow the separation of
the role of CYP3A4 and P- gp in these interactions.
All glucocorticoids are readily eliminated by metabolism. Although the role of
individual CYP enzymes in the metabolic pathways of various glucocorticoids
remains unclear, CYP3A4 probably has a dissimilar role in the metabolism of
each glucocorticoid. Based on the studies presented here, itraconazole, a potent
inhibitor of CYP3A4, greatly interacted with both methylprednisolone and
dexamethasone, but only slightly affected the pharmacokinetics of prednisolone.
This strongly suggests that the metabolic pathways of these glucocorticoids are
dissimilar and that, in contrast to prednisolone, CYP3A4 has an important role in
the metabolism of methylprednisolone and dexamethasone.
Induction of CYP3A4 by glucocorticoids may counteract the effects of CYP3A4
inhibitors on these glucocorticoids during long-term use. Dexamethasone has been
shown to induce CYP3A4 in vitro (Pichard et al 1992), and in cancer patients to
increase the Cl of cyclophosphamide, a substrate for CYP3A4 (Yule et al 1996,
Busse et al 1997). However, in controlled studies, dexamethasone does not affect
the AUC of triazolam and midazolam, both known substrates for CYP3A4
(Villikka et al 1998, Palmer et al 2000). Thus, dexamethasone seems not to be a
potent inducer of CYP3A4-mediated metabolism in human beings.
The concomitant use of the CYP3A4 inhibitors itraconazole, diltiazem, or
mibefradil with methylprednisolone, and of itraconazole with dexamethasone
markedly enhanced the adrenal-suppressant effect of these glucocorticoids. The
prologned suppression was due to the increased effect of methylprednisolone or
dexamethasone, because neither itraconazole, diltiazen nor mibefradil
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significantly affected the plasma cortisol concentrations measured in the morning
before glucocorticoid administration. The marked decrease in elimination of
methylprednisolone and dexamethasone is particularly important, because it
appears also to prolong the biological half-lives of these steroids. Thus, not only
the exposure to methylprednisolone and dexamethasone increased, but also the
”biological profile” of these steroids changed. Furthermore, the increased
exposure to methylprednisolone, especially during night-time, enhanced its
adrenal-suppressant effect by suppressing the peak cortisol concentration evident
during the placebo phase. This may be important in patients receiving low doses
of methylprednisolone once daily.
Present studies were performed in healthy volunteers after administration of a
single dose of glucocorticoid. It can be assumed, however, that the great effect of
CYP3A4 inhibitors on the pharmacokinetics and pharmacodynamics of
methylprednisolone or dexamethasone can be seen also in patients receiving long-
term glucocorticoid treatment. During long-term treatment, the increased and
prolonged exposure to glucocorticoids caused by other concomitant medication
may alter the clinical response to glucocorticoid. Besides plasma cortisol
concentratios and the addrenal-suppressant effect of glucocorticoid, no other
pharmacodynamic parameters were assessed in the studies of this thesis. However,
there are several lines of evidence in the literature to suggest that concomitant use
of a potent inhibitor of CYP3A4 with glucocorticoid, or increased exposure to a
glucocorticoid may enhance many different glucocorticoid-related effects.
In one case report, addition of itraconazole to a transplant patient´s
immunosuppressive regimen which includied methylprednisolone led to myopathy
and diabetes, suggesting a clinically important interaction between itraconazole
and methylprednisolone (Linthoudt et al 1996). Similar, or even more severe
itraconazole-methylprednisolone interactions are known to have occurred during
their combined clinical use. Furthermore, combination of troleandomycin and
methylprednisolone had a beneficial ”steroid-sparing” effect on difficult asthma
(Siracusa et al 1993). However, this combination led to increased risk of
glucocorticoid-related adverse effects (e.g., reduction in bone mineral content,
increase in plasma glucose levels), and even one case of fatal varicella has been
reported, suggesting enhanced immunosuppression (Harris et al 1989, Siracusa et
al 1993, Lantner et al 1990). Diltiazem and verapamil can improve the outcome of
organ-transplant patients treated with methylprednisone (Wagner et al 1987,
Kunzendorf et al 1991, Dawidson et al 1989, Mies et al 1998), which may in part
be explained by the increase in the AUC of methylprednisolone caused by
diltiazem. Furthermore, methylprednisolone exposure rather than the
methylprednisolone dose predicts adrenal suppression and growth inhibition in
children with liver and renal transplants (Sarna et al 1997). In addition, the
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diabetogenic effect of dexamethasone appears to be dose-dependent (Matsumoto
et al 1996).
The pharmacokinetic interaction between itraconazole and dexamethasone and
between itraconazole and methylprednisolone was slightly greater after oral than
after intravenous administration of these two steroids. This finding may favour
intravenous rather than oral use of methylprednisolone and dexamethasone.
However, the extent of the adrenal-suppressant effect was similar after their oral
and their intravenous administration. The extent of interaction observed after oral
administration might be reduced by giving itraconazole some 12 h after
glucocorticoid, as shown in a recent study of ketoconazole with budesonide
(Seidegård 2000).
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One of the most important drug-metabolising enzymes in human beings is
CYP3A4. Many drugs and also grapefruit juice can inhibit the catalytic activity
of CYP3A4, which may result in a clinically significant increase in exposure to
drugs metabolised mainly by this enzyme.
The systemic glucocorticoids methylprednisolone, prednisolone, and
dexamethasone have been used for many years for various clinical indications
and are eliminated mainly by metabolism. Although the role of individual CYP
enzymes in the metabolic pathways of these glucocorticoids seems not to be
clear, CYP3A4 probably plays a dissimilar role in their metabolism.
The aim of this series of studies was to investigate the effect of CYP3A4
inhibitors on the pharmacokinetics and pharmacodynamics of systemic
glucocorticoids: the effect of itraconazole on oral (Study I) and intravenous
(Study II) methylprednisolone, on oral prednisolone (Study IV), and on oral and
intravenous dexamethasone (Study VI). In addition, the effect of diltiazem or
mibefradil (Study III), and grapefruit juice (Study V) on oral methylprednisolone
was investigated. The effect of route of administration of methylprednisolone and
dexamethasone on their possible interaction with itraconazole was also evaluated
(Studies I, II, and VI).
The studies were double-blind, randomised, placebo-controlled, and cross-over,
except for the grapefruit juice-methylprednisolone interaction study, which had
an open, randomised, cross-over design. All studies were carried out in 8 to 10
healthy subjects. A single dose of glucocorticoid was administered after or during
the administration of a CYP3A4 inhibitor for 3 to 4 days. Blood samples were
collected, and plasma drug and cortisol concentrations determined by specific
high-performance liquid chromatographic and mass spectrometric methods.
Itraconazole increased the AUC of oral and intravenous methylprednisolone 3.9-
fold (p <0.001) and 2.6-fold (p <0.001). The AUC of oral and intravenous
dexamethasone was increased 3.7-fold (p <0.001) and 3.3-fold (p <0.001) by
itraconazole. The use of itraconazole enhanced the adrenal-suppressant effect of
both methylprednisolone and dexamethasone. In contrast, itraconazole increased
the AUC of oral prednisolone by only 24% (p <0.001) and had a minor effect on
the adrenal-suppressant effect of prednisolone. Both diltiazem and mibefradil
increased the AUC of oral methylprednisolone (2.6-fold and 3.8-fold; p <0.001)
and greatly enhanced the adrenal-suppressant effect of methylprednisolone.
Grapefruit juice increased the AUC of oral methylprednisolone by 75% (p
<0.001); however, it did not significantly affect the adrenal-suppressant effect of
methylprednisolone. The route of methylprednisolone or dexamethasone
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administration may have a only minor effect on the extent of itraconazole-
methylprednisolone and itraconazole-dexamethasone interactions.
The following conclusions can be drawn on the basis of Studies I-VI:
1. Interactions between the antifungal agent itraconazole and methylprednisolone
or dexamethasone are clinically important. Itraconazole and probably also other
potent CYP3A4 inhibitors should be used with caution in patients receiving
dexamethasone or methylprednisolone, particularly during long-term
concomitant use.
2. The interaction between itraconazole and prednisolone is unlikely to be
clinically significant.
3. The interactions between the calcium-channel blockers diltiazem or mibefradil
and methylprednisolone are clinically important. Diltiazem and mibefradil
should be used with caution in patients receiving methylprednisolone,
particularly during long-term concomitant use.
4. The clinical significance of the interaction between grapefruit juice and oral
methylprednisolone is probably minor. However, high repeated doses of
grapefruit juice may enhance the effects of oral methylprednisolone in some
sensitive subjects.
5. The route of methylprednisolone or dexamethasone administration may have a
minor effect on the extent of itraconazole-methylprednisolone and itraconazole-
dexamethasone interactions. Despite the differences seen in pharmacokinetic
interactions, the extent of the adrenal-suppressant effect was similar after oral or
intravenous dose of these glucocorticoids.
6. All of these interactions are probably due to inhibition of the CYP3A4 enzyme
during both the first-pass and the elimination phases. Inhibition of the P-
glycoprotein may have contributed to the observed interactions of
methylprednisolone and of dexamethasone.
7. The metabolism and interaction potential of different glucocorticoids are
dissimilar. In contrast to prednisolone and also prednisone, CYP3A4 appears to
be important in the metabolism of methylprednisolone and dexamethasone.
Therefore, the pharmacokinetics of methylprednisolone and dexamethasone are
sensitive to itraconazole and probably also to other potent CYP3A4 inhibitors.
However, interactions of itraconazole and other CYP3A4 inhibitors with
prednisolone and probably with prednisone are likely to be of limited clinical
significance.
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